Collection coverage
Benchmark results and remaining gaps
See which pages have checked results and charts, and which still need their published evidence collected.
Release 2026-11-21-adc15377fab2. Counts include results reached through source-backed membership links. A metric row is not an independent experiment. Charts keep a source, protocol, dataset and metric together.
Pages without results indicate gaps in this collection. A paper may contain experiments we have not yet transcribed. We do not substitute unrelated results or zero scores for missing evidence.
Download the complete audit (JSON) (gzip)
Benchmarks
126 pages · 57 with results · 38 with charts.
| Page | Evaluations and metric rows | Charts | Collection status |
|---|---|---|---|
| AlphaFold and ESMFold benchmark on PDB structures released 2022 to 2024 | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| ATOM3D | 57 evaluations · 57 rows | 14 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BacBench | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BEACON | 221 evaluations · 221 rows | 13 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE | 384 evaluations · 588 rows | 71 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BenchBench-Cloning | 24 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BenchBench-Cloning construct-design set | 24 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BenchBench-Cloning protocol-development set | 56 evaluations · 56 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BEND | 169 evaluations · 169 rows | 7 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Benet-Pages 2025 BRCA1/BRCA2 VUS reclassification study | 2 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BERTax taxonomic classification of genome fragments (Mock et al. 2022) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Brandes et al. 2023 clinical missense pathogenicity benchmarks (ClinVar and HGMD/gnomAD) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Brandes et al. 2023 ClinVar in-frame indel and stop-gain pathogenicity benchmarks | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| CACHE Challenge #3 | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| CAFA | 438 evaluations · 438 rows | 6 source-scoped figures | Checked result tables available.Scope and remaining work
|
| CAMI | 16 evaluations · 256 rows | 16 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Cancer Immunotherapy Data Science Challenge | 54 evaluations · 54 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CAPRI | 100 evaluations · 400 rows | 16 source-scoped figures | Checked result tables available.Scope and remaining work
|
| CASP | 90 evaluations · 270 rows | 6 source-scoped figures | Checked result tables available.Scope and remaining work
|
| CASP16 binding affinity challenge | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| CIViC MCP 2026 evidence-retrieval evaluation | 3 evaluations · 162 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClinBench (Blank Bio) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| ClinGen SVI calibration of computational predictors for PP3/BP4 | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| ClusPro Protein Docking Benchmark 5.0 study | 16 evaluations · 111 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DART-Eval | 316 evaluations · 316 rows | 23 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Davis and KIBA drug-target affinity benchmark (DeepDTA split) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| DeepProtein benchmark | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| DEKOIS 2.0 | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Differential expression classification benchmark for perturbation models (Sun et al. 2026) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| DNALONGBENCH | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| DUD-E (Directory of Useful Decoys, Enhanced) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| ENIGMA 2024 BRCA evidence-calibration and curation study | 5 evaluations · 39 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ESMFold2 Runs N’ Poses comparison | 11 evaluations · 11 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Evo 2 7B on BRCA1 saturation genome editing SNVs across cloud GPUs (Rewire, evo2-cloud-operations) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Evo 2 paper zero-shot human variant effect evaluations (Brixi et al. 2026) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| FLIP | 155 evaluations · 155 rows | 15 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP2 | 149 evaluations · 293 rows | 33 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FoldBench | 45 evaluations · 175 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FramePool translation-prediction study | 30 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Gene-MTEB | 80 evaluations · 80 rows | 16 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GENEB | 22 evaluations · 22 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GENEB leaderboard | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| GeneRNIB | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Genie 3 unconditional short monomer comparison | 13 evaluations · 65 rows | 5 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks | 18 evaluations · 36 rows | 18 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GFMBench-API | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| GlycanML | 323 evaluations · 323 rows | 50 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GPCRrecent | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| GPN paper: Arabidopsis thaliana held-out sequence modelling and embedding evaluation | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| GPN paper: unsupervised variant effect prediction in Arabidopsis thaliana | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| GPN-MSA variant effect prediction evaluation (Benegas et al.) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| GPN-Star variant effect prediction benchmarks (Ye et al. 2026) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| GUANinE v1.1 | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| GUE | 280 evaluations · 280 rows | 28 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Harmonised single-cell and spatial foundation model benchmark (Chen et al. 2026) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| HECTOR 2026 preprint: ENIGMA Evidence Repository validation | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HEST-Benchmark | 100 evaluations · 100 rows | 10 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Hu 2026 BRCA2 integrated functional-data classification study | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HyCell report benchmark on seven held-out atlases | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| HyInv technical report inverse-folding comparison | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| HyPLM technical report protein language model evaluation | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Jores plant promoter prediction study | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| LiPP benchmark set | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| LIT-PCBA | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Livesey and Marsh variant effect predictor benchmark (2025 edition) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Ludaic and Elofsson 2026 RNA structure benchmark | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| M. tuberculosis read classification with standard and custom databases (Hall and Coin 2024) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| MassSpecGym | 24 evaluations · 116 rows | 28 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MetageNN long-read genus classification benchmark (Peres da Silva et al. 2024) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| MF-PCBA | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| MIST CANOPUS molecular retrieval | 6 evaluations · 45 rows | 8 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Mock community taxonomic profiling benchmark (Portik et al. 2022) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| MPRabc K562 enhancer–gene evaluation | 6 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| mRNABench | 696 evaluations · 700 rows | 26 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval evaluations | 63 evaluations · 189 rows | 24 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench | 1,101 evaluations · 1,101 rows | 43 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Nucleotide Transformer benchmark (18 tasks) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| OncoVI 2026 oncogenicity evaluation study | 5 evaluations · 27 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Open Problems | 384 evaluations · 384 rows | 24 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PepSpecBench | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Perturbation-target prediction from attention-derived edge scores (Kendiukhov 2026, Objective B) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| PerturBench | 76 evaluations · 76 rows | 8 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PEtab benchmark collection | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| PFMBench | 141 evaluations · 141 rows | 12 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PLABench | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Plant Genomic Benchmark (PGB) | 24 evaluations · 24 rows | 12 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Plasma mcfDNA sequencing for predicting and diagnosing bloodstream infection in high-risk leukaemia (Wolf et al. 2026) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| PLINDER | 7 evaluations · 33 rows | 5 source-scoped figures | Checked result tables available.Scope and remaining work
|
| POISK co-folding binder-versus-decoy benchmark | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| PRIME viral mutation-space evaluation | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Protein embeddings for GNN PPI prediction (OGBl-ppa and HuRI) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| ProteinBench | 556 evaluations · 556 rows | 95 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym | 284 evaluations · 2,074 rows | 17 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Public binding free energy benchmark (Ross et al. 2023) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| RFD4-Proteina frozen project benchmark, October 9 2026 supplement | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| RhoFold+ CASP15 natural RNA comparison | 56 evaluations · 112 rows | 12 source-scoped figures | Checked result tables available.Scope and remaining work
|
| RhoMax original wavelength-prediction comparison | 15 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RNAGym fitness leaderboard v0.1.1 | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Scaffold-Lab unconditional generation | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| scFoundation cell-type annotation comparison | 14 evaluations · 14 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Sci-Plex highest-dosage holdout benchmark (GIM protocol) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| scIB | 69 evaluations · 821 rows | 13 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SCMBench | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| scTab published annotation evaluation | 21 evaluations · 26 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SegmentNT human genome annotation | 294 evaluations · 588 rows | 28 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SEQC2 HCC1395 somatic CNV benchmark | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Short-read versus host-depleted nanopore mNGS on BALF (Hu et al. 2026) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| So 2024 BRCA1 ClinVar conflicting-variant reinterpretation study | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Static GRN reconstruction from single-cell foundation models (Ye et al. 2026) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Talos 2026 evaluation and reanalysis study | 14 evaluations · 82 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TAPE | 50 evaluations · 50 rows | 5 source-scoped figures | Checked result tables available. |
| TDC molecular tasks | 66 evaluations · 66 rows | 22 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TorchCraft 10-ligand pocket design benchmark | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| TorchCraft 12-target minibinder design benchmark | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| TorchCraft 15-target VHH design benchmark | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| TorchCraft 8-target cyclic peptide design benchmark | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| TorchCraft runtime benchmark across sequence lengths | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| TraitGym | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Universal antibody-antigen affinity evaluation on AlphaBind (MochiBind study) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| ViroBench | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Virtual Cell Challenge 2026 | 1,048 evaluations · 1,048 rows | 14 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Virus profiler benchmark against a shared Virus Pathogen Database (Tisza et al. 2026) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Zero-shot cell embedding evaluation of single-cell foundation models (Kedzierska et al. 2025) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Zero-shot RNA language model benchmark (Wang et al. 2026) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
Tasks
552 pages · 488 with results · 389 with charts.
| Page | Evaluations and metric rows | Charts | Collection status |
|---|---|---|---|
| A-to-I RNA editing site prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| antibody deamidation-site prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Antibody loop structure prediction | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Antibody–antigen interaction prediction using folded complexes | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| antigen-antibody HIV neutralization prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ATOM3D LBA-RMSE: Ligand binding affinity, root mean squared error | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ATOM3D LBA-RP: Ligand binding affinity, global Pearson correlation | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ATOM3D LBA-RS: Ligand binding affinity, global Spearman correlation | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ATOM3D LEP-AUROC: Ligand efficacy prediction | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ATOM3D MSP: Mutation stability prediction | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ATOM3D PIP: Protein interface prediction | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ATOM3D PSR-GLOBAL-RS: Protein structure ranking, global Spearman | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ATOM3D PSR-MEAN-RS: Protein structure ranking, mean Spearman within a target | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ATOM3D RES: Residue identity | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ATOM3D RSR-GLOBAL-RS: RNA structure ranking, global Spearman | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ATOM3D RSR-MEAN-RS: RNA structure ranking, mean Spearman within a target | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ATOM3D SMP-EGAP: Small molecule properties, HOMO-LUMO gap | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ATOM3D SMP-MU: Small molecule properties, dipole moment | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ATOM3D SMP-U0AT: Small molecule properties, atomization energy | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BacBench Antibiotic resistance prediction | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BacBench Essential gene prediction | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BacBench Operon identification from long-read RNA sequencing | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BacBench Phenotypic trait prediction | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BacBench Protein-protein interaction prediction | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BacBench Strain clustering | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Bacterial promoter prediction | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Batch integration | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BEACON APA: Alternative polyadenylation isoform prediction | 17 evaluations · 17 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEACON CMP: Contact map prediction | 17 evaluations · 17 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEACON CRI-Off: CRISPR off-target effect prediction | 17 evaluations · 17 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEACON CRI-On: CRISPR on-target efficiency prediction | 17 evaluations · 17 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEACON DMP: Distance map prediction | 17 evaluations · 17 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEACON Modif: RNA modification site prediction | 17 evaluations · 17 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEACON MRL: Mean ribosome loading prediction | 17 evaluations · 17 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEACON ncRNA: Non-coding RNA family classification | 17 evaluations · 17 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEACON PRS: Programmable RNA switch prediction | 17 evaluations · 17 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEACON SPL: Splice site prediction | 17 evaluations · 17 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEACON SSI: Structure score imputation | 17 evaluations · 17 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEACON SSP: Secondary structure prediction | 17 evaluations · 17 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEACON VDP: Vaccine degradation prediction | 17 evaluations · 17 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BenchBench-Cloning construct design: AG/AP1 chimera plasmid | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BenchBench-Cloning construct design: Alkaloid-pathway GoldenBraid set | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BenchBench-Cloning construct design: Detector choice from antibody data | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BenchBench-Cloning construct design: Dual-luciferase frame panel | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BenchBench-Cloning construct design: GFP into EcoFlex vector | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BenchBench-Cloning construct design: Insulin intermediate construct | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BenchBench-Cloning construct design: Insulin two-chain constructs | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BenchBench-Cloning construct design: Matched promoter panel | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BenchBench-Cloning construct design: Minimal-edit recoding | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BenchBench-Cloning construct design: MPRA construct rebuild | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BenchBench-Cloning construct design: Prime-assembly donor family | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BenchBench-Cloning construct design: Reporter choice from data | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BenchBench-Cloning construct design: Sodium-channel promoter repair | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BenchBench-Cloning construct design: Synthetic-chromosome locus edit | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BenchBench-Cloning construct design: Tus/TerB HEK293 constructs | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BEND CHROMATIN: Chromatin accessibility | 23 evaluations · 23 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEND CPG: CpG methylation | 24 evaluations · 24 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEND ENHANCER: Enhancer annotation | 25 evaluations · 25 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEND GENE-FINDING: Gene finding | 25 evaluations · 25 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEND HISTONE: Histone modification | 24 evaluations · 24 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEND VARIANT-DISEASE: Noncoding variant effects on disease | 24 evaluations · 24 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEND VARIANT-EXPRESSION: Noncoding variant effects on expression | 24 evaluations · 24 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BioML-bench task CBX4_HUMAN_multi-sub | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task CSN4_MOUSE_indels | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task open-problems-cell-communication | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task open-problems-label-projection | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task open-problems-modality | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task open-problems-perturbations | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task open-problems-spatial-genes | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task polaris-adme-fang-hclint-1 | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task polaris-adme-fang-hppb-1 | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task polaris-adme-fang-solu-1 | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task polaris-pkis2-egfr-wt-c-1 | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task PSAE_PICP2_indels | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task Q8EG35_SHEON_indels | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task SPA_STAAU_Tsuboyama_2023 | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task SPIKE_SARS2_Starr_2020 | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task tdcommons-bbb-martins | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task tdcommons-caco2-wang | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task tdcommons-cyp2d6-substrate | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task tdcommons-herg | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BioML-bench task tdcommons-lipophilicity | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Biomolecular complex structure | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| CAMI genome binning | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| CAMI II phylum read classification | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CAMI II superkingdom read classification | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CAMI metagenome assembly | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| CAMI taxonomic binning | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| CAMI taxonomic profiling | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| CATH superfamily annotation | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| cell-type annotation | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Cell-type annotation | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Cell-type deconvolution of bulk RNA-seq with single-cell references | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Cell-type identification | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Cell-type structure in frozen embeddings | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| clathrin protein classification | 14 evaluations · 79 rows | 6 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Clinical missense variant pathogenicity classification | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| ClinVar 3-prime UTR variant classification | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Combinatorial cell-label classification | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Community profiling | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Cross-dataset single-cell drug response transfer | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Cross-platform scATAC cell-type annotation | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| cross-species conservation prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Cyclic peptide design against a protein target | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| DART-Eval CA-AUROC-GM12878: Chromatin activity prediction, GM12878, positives against negatives | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval CA-AUROC-H1ESC: Chromatin activity prediction, H1ESC, positives against negatives | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval CA-AUROC-HEPG2: Chromatin activity prediction, HEPG2, positives against negatives | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval CA-AUROC-IMR90: Chromatin activity prediction, IMR90, positives against negatives | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval CA-AUROC-K562: Chromatin activity prediction, K562, positives against negatives | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval CA-SPEARMAN-GM12878: Chromatin activity prediction, GM12878, positives only | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval CA-SPEARMAN-H1ESC: Chromatin activity prediction, H1ESC, positives only | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval CA-SPEARMAN-HEPG2: Chromatin activity prediction, HEPG2, positives only | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval CA-SPEARMAN-IMR90: Chromatin activity prediction, IMR90, positives only | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval CA-SPEARMAN-K562: Chromatin activity prediction, K562, positives only | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval CTS-ACC: Cell-type-specific element classification, overall accuracy | 14 evaluations · 14 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval CTS-GM12878: Cell-type-specific element classification, GM12878 | 14 evaluations · 14 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval CTS-H1ESC: Cell-type-specific element classification, H1ESC | 14 evaluations · 14 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval CTS-HEPG2: Cell-type-specific element classification, HEPG2 | 14 evaluations · 14 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval CTS-IMR90: Cell-type-specific element classification, IMR90 | 14 evaluations · 14 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval CTS-K562: Cell-type-specific element classification, K562 | 14 evaluations · 14 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval REI-ABS: Regulatory element identification, absolute accuracy | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval REI-ACC: Regulatory element identification, zero-shot accuracy | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval REI-PAIR: Regulatory element identification, paired accuracy | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval VS-AFRICAN-AUROC: Variant scoring on Chromatin QTLs in African LCLs, AUROC | 22 evaluations · 22 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval VS-AFRICAN-PEARSON_R: Variant scoring on Chromatin QTLs in African LCLs, Pearson r | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval VS-YORUBAN-AUROC: Variant scoring on DNase QTLs in Yoruban LCLs, AUROC | 22 evaluations · 22 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DART-Eval VS-YORUBAN-PEARSON_R: Variant scoring on DNase QTLs in Yoruban LCLs, Pearson r | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| De novo minibinder design against a protein target | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| differentially expressed gene identification | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Discriminating antibody binders from sequence-similar putative non-binders | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| DNA-binding residue prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Donor-aware age-class prediction | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Donor-held-out reference mapping | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| E. coli sigma70 promoter prediction | 15 evaluations · 60 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| E. coli sigma70 promoter prediction | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Enhancer / MPRA effects | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Enhancer classification | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| enhancer prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| enhancer prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| enhancer recognition | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Enhancer-target gene prediction | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Enzyme functional identity prediction | 5 evaluations · 40 rows | 8 source-scoped figures | Checked result tables available.Scope and remaining work
|
| extremely long RNA species classification | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FLIP AAV-1-VS-REST: AAV fitness prediction, 1-vs-rest split | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP AAV-2-VS-REST: AAV fitness prediction, 2-vs-rest split | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP AAV-7-VS-REST: AAV fitness prediction, 7-vs-rest split | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP AAV-DES-MUT: AAV fitness prediction, Des-Mut split | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP AAV-LOW-VS-HIGH: AAV fitness prediction, low-vs-high split | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP AAV-MUT-DES: AAV fitness prediction, Mut-Des split | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP GB1-1-VS-REST: GB1 fitness prediction, 1-vs-rest split | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP GB1-2-VS-REST: GB1 fitness prediction, 2-vs-rest split | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP GB1-3-VS-REST: GB1 fitness prediction, 3-vs-rest split | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP GB1-LOW-VS-HIGH: GB1 fitness prediction, low-vs-high split | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP RANDOM-SAMPLED-SPLITS-AAV: Random sampled splits fitness prediction, AAV split | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP RANDOM-SAMPLED-SPLITS-GB1: Random sampled splits fitness prediction, GB1 split | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP THERMOSTABILITY-HUMAN-CELL: Thermostability fitness prediction, Human-Cell split | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP THERMOSTABILITY-HUMAN: Thermostability fitness prediction, Human split | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP THERMOSTABILITY-MIXED: Thermostability fitness prediction, Mixed split | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| flu-vaccine mRNA property prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Framework-conditioned VHH design against a protein target | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| G-quadruplex classification | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| gene fusion breakpoint classification | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Gene-regulatory link prediction | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| gene-regulatory signal prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GENEB LINEAR-PROBE: Average macro-MCC across the 13 representative tasks, linear probe | 11 evaluations · 11 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GENEB MLP-PROBE: Average macro-MCC across the 13 representative tasks, MLP probe | 11 evaluations · 11 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genome-wide prophage detection | 17 evaluations · 102 rows | 6 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks DEMO-CODING-VS-INTERGENOMIC-SEQS-ACCURACY: demo_coding_vs_intergenomic_seqs, Accuracy | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks DEMO-CODING-VS-INTERGENOMIC-SEQS-F1: demo_coding_vs_intergenomic_seqs, F1 score | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks DEMO-HUMAN-OR-WORM-ACCURACY: demo_human_or_worm, Accuracy | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks DEMO-HUMAN-OR-WORM-F1: demo_human_or_worm, F1 score | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks DROSOPHILA-ENHANCERS-STARK-ACCURACY: drosophila_enhancers_stark, Accuracy | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks DROSOPHILA-ENHANCERS-STARK-F1: drosophila_enhancers_stark, F1 score | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks DUMMY-MOUSE-ENHANCERS-ENSEMBL-ACCURACY: dummy_mouse_enhancers_ensembl, Accuracy | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks DUMMY-MOUSE-ENHANCERS-ENSEMBL-F1: dummy_mouse_enhancers_ensembl, F1 score | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks HUMAN-ENHANCERS-COHN-ACCURACY: human_enhancers_cohn, Accuracy | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks HUMAN-ENHANCERS-COHN-F1: human_enhancers_cohn, F1 score | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks HUMAN-ENHANCERS-ENSEMBL-ACCURACY: human_enhancers_ensembl, Accuracy | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks HUMAN-ENHANCERS-ENSEMBL-F1: human_enhancers_ensembl, F1 score | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks HUMAN-ENSEMBL-REGULATORY-ACCURACY: human_ensembl_regulatory, Accuracy | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks HUMAN-ENSEMBL-REGULATORY-F1: human_ensembl_regulatory, F1 score | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks HUMAN-NONTATA-PROMOTERS-ACCURACY: human_nontata_promoters, Accuracy | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks HUMAN-NONTATA-PROMOTERS-F1: human_nontata_promoters, F1 score | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks HUMAN-OCR-ENSEMBL-ACCURACY: human_ocr_ensembl, Accuracy | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genomic Benchmarks HUMAN-OCR-ENSEMBL-F1: human_ocr_ensembl, F1 score | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML glycosylation type prediction | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML immunogenicity prediction | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML protein-glycan interaction prediction | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML taxonomy prediction | 190 evaluations · 190 rows | 26 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE CORE-PROMOTER-DETECTION-ALL: Core promoter detection, dataset all | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE CORE-PROMOTER-DETECTION-NOTATA: Core promoter detection, dataset notata | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE CORE-PROMOTER-DETECTION-TATA: Core promoter detection, dataset tata | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE COVID-VARIANT-CLASSIFICATION-COVID: Covid variant classification, dataset Covid | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE EPIGENETIC-MARKS-PREDICTION-H3: Epigenetic marks prediction, dataset H3 | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE EPIGENETIC-MARKS-PREDICTION-H3K14AC: Epigenetic marks prediction, dataset H3K14ac | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE EPIGENETIC-MARKS-PREDICTION-H3K36ME3: Epigenetic marks prediction, dataset H3K36me3 | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE EPIGENETIC-MARKS-PREDICTION-H3K4ME1: Epigenetic marks prediction, dataset H3K4me1 | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE EPIGENETIC-MARKS-PREDICTION-H3K4ME2: Epigenetic marks prediction, dataset H3K4me2 | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE EPIGENETIC-MARKS-PREDICTION-H3K4ME3: Epigenetic marks prediction, dataset H3K4me3 | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE EPIGENETIC-MARKS-PREDICTION-H3K79ME3: Epigenetic marks prediction, dataset H3K79me3 | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE EPIGENETIC-MARKS-PREDICTION-H3K9AC: Epigenetic marks prediction, dataset H3K9ac | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE EPIGENETIC-MARKS-PREDICTION-H4: Epigenetic marks prediction, dataset H4 | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE EPIGENETIC-MARKS-PREDICTION-H4AC: Epigenetic marks prediction, dataset H4ac | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE PROMOTER-DETECTION-ALL: Promoter detection, dataset all | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE PROMOTER-DETECTION-NOTATA: Promoter detection, dataset notata | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE PROMOTER-DETECTION-TATA: Promoter detection, dataset tata | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE SPLICE-SITE-PREDICTION-RECONSTRUCT: Splice site prediction, dataset Reconstruct | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE TRANSCRIPTION-FACTOR-PREDICTION-HUMAN-0: Transcription factor prediction (human), dataset 0 | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE TRANSCRIPTION-FACTOR-PREDICTION-HUMAN-1: Transcription factor prediction (human), dataset 1 | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE TRANSCRIPTION-FACTOR-PREDICTION-HUMAN-2: Transcription factor prediction (human), dataset 2 | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE TRANSCRIPTION-FACTOR-PREDICTION-HUMAN-3: Transcription factor prediction (human), dataset 3 | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE TRANSCRIPTION-FACTOR-PREDICTION-HUMAN-4: Transcription factor prediction (human), dataset 4 | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE TRANSCRIPTION-FACTOR-PREDICTION-MOUSE-0: Transcription factor prediction (mouse), dataset 0 | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE TRANSCRIPTION-FACTOR-PREDICTION-MOUSE-1: Transcription factor prediction (mouse), dataset 1 | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE TRANSCRIPTION-FACTOR-PREDICTION-MOUSE-2: Transcription factor prediction (mouse), dataset 2 | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE TRANSCRIPTION-FACTOR-PREDICTION-MOUSE-3: Transcription factor prediction (mouse), dataset 3 | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GUE TRANSCRIPTION-FACTOR-PREDICTION-MOUSE-4: Transcription factor prediction (mouse), dataset 4 | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Held-out-clade classification | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| HEST-Benchmark CCRCC: Gene expression prediction from histology, Clear cell renal cell carcinoma | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| HEST-Benchmark COAD: Gene expression prediction from histology, Colon adenocarcinoma | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| HEST-Benchmark HCC: Gene expression prediction from histology, Hepatocellular carcinoma | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| HEST-Benchmark IDC: Gene expression prediction from histology, Invasive ductal carcinoma | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| HEST-Benchmark LUNG: Gene expression prediction from histology, Lung | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| HEST-Benchmark LYMPH_IDC: Gene expression prediction from histology, Lymph node metastasis of invasive ductal carcinoma | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| HEST-Benchmark PAAD: Gene expression prediction from histology, Pancreatic adenocarcinoma | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| HEST-Benchmark PRAD: Gene expression prediction from histology, Prostate adenocarcinoma | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| HEST-Benchmark READ: Gene expression prediction from histology, Rectum adenocarcinoma | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| HEST-Benchmark SKCM: Gene expression prediction from histology, Skin cutaneous melanoma | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Hierarchical metagenomic taxonomy classification | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Homolog-like variant generation from a seed antibody sequence | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Human 5mC detection | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| human core-promoter classification | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| human protein-protein interaction prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| human RNA 2-prime-O-methylation site prediction | 12 evaluations · 84 rows | 14 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Human thymus cell-type classification | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| human-versus-viral protein classification | 8 evaluations · 32 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Immunotherapy response from pretreatment bulk RNA-seq | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Intrinsically disordered protein ensemble docking | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Isoform usage recovery from gene-level expression | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Ligand potency prediction using generated poses | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ligand-conditioned protein pocket design | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Lipid–protein binding pose | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Long-range regulation | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Long-read taxonomic profiling | 9 evaluations · 23 rows | 3 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MassSpecGym De novo molecule generation | 6 evaluations · 36 rows | 12 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MassSpecGym Molecule retrieval | 10 evaluations · 40 rows | 8 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MassSpecGym Spectrum simulation | 8 evaluations · 40 rows | 8 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Mean ribosome load from MPRA | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| metagenomic genus classification | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Metagenomic taxonomic classification | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MFASS splice-variant prioritisation | 9 evaluations · 31 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| microbiome disease-state classification | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| miRNA-mRNA interaction prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Mock-community MAG taxonomy classification | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Monomer structure | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| mRNA half-life prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| mRNA-protein interaction prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| mRNABench ECLIP: eCLIP binding site prediction | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| mRNABench GO: Gene Ontology term prediction | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| mRNABench HL: mRNA half life | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| mRNABench MRL-HL-PAIR: Paired mean ribosome load and half life | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| mRNABench MRL-MPRA: Mean ribosome load on an MPRA library | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| mRNABench MRL: Mean ribosome load | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| mRNABench MRNA-LOC-LR: mRNA localisation, long range | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| mRNABench MRNA-LOC-SR: mRNA localisation, short range | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| mRNABench PROT-LOC: Protein localisation | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| mRNABench VEP: Variant effect prediction | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Multi-species prokaryotic promoter detection | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Mutated RBD binding prediction | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NABench CCV-CORR-APTAMER: Fitness prediction on aptamer assays, supervised, contiguous cross validation | 25 evaluations · 25 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench CCV-CORR-ENHANCER: Fitness prediction on enhancer assays, supervised, contiguous cross validation | 25 evaluations · 25 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench CCV-CORR-MRNA: Fitness prediction on mRNA assays, supervised, contiguous cross validation | 25 evaluations · 25 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench CCV-CORR-PROMOTER: Fitness prediction on promoter assays, supervised, contiguous cross validation | 23 evaluations · 23 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench CCV-CORR-RIBOZYME: Fitness prediction on ribozyme assays, supervised, contiguous cross validation | 25 evaluations · 25 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench CCV-CORR-TRNA: Fitness prediction on tRNA assays, supervised, contiguous cross validation | 24 evaluations · 24 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench DMS-CCV: Overall fitness prediction on NABench deep mutational scanning assays, Contiguous cross validation Spearman ρ | 25 evaluations · 25 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench DMS-FS: Overall fitness prediction on NABench deep mutational scanning assays, Few-shot Spearman ρ | 25 evaluations · 25 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench DMS-RCV: Overall fitness prediction on NABench deep mutational scanning assays, Random cross validation Spearman ρ | 25 evaluations · 25 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench DMS-ZS-AUC: Overall fitness prediction on NABench deep mutational scanning assays, Zero-shot AUC | 25 evaluations · 25 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench DMS-ZS-CORR: Overall fitness prediction on NABench deep mutational scanning assays, Zero-shot Spearman ρ | 25 evaluations · 25 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench DMS-ZS-MCC: Overall fitness prediction on NABench deep mutational scanning assays, Zero-shot MCC | 25 evaluations · 25 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench DMS-ZS-NDCG: Overall fitness prediction on NABench deep mutational scanning assays, Zero-shot NDCG | 25 evaluations · 25 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench FS-CORR-APTAMER: Fitness prediction on aptamer assays, few-shot | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench FS-CORR-ENHANCER: Fitness prediction on enhancer assays, few-shot | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench FS-CORR-MRNA: Fitness prediction on mRNA assays, few-shot | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench FS-CORR-PROMOTER: Fitness prediction on promoter assays, few-shot | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench FS-CORR-RIBOZYME: Fitness prediction on ribozyme assays, few-shot | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench FS-CORR-TRNA: Fitness prediction on tRNA assays, few-shot | 25 evaluations · 25 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench RCV-CORR-APTAMER: Fitness prediction on aptamer assays, supervised, random cross validation | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench RCV-CORR-ENHANCER: Fitness prediction on enhancer assays, supervised, random cross validation | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench RCV-CORR-MRNA: Fitness prediction on mRNA assays, supervised, random cross validation | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench RCV-CORR-PROMOTER: Fitness prediction on promoter assays, supervised, random cross validation | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench RCV-CORR-RIBOZYME: Fitness prediction on ribozyme assays, supervised, random cross validation | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench RCV-CORR-TRNA: Fitness prediction on tRNA assays, supervised, random cross validation | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench SELEX-FS: Overall fitness prediction on NABench SELEX assays, Few-shot Spearman ρ | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench SELEX-RCV: Overall fitness prediction on NABench SELEX assays, Random cross validation Spearman ρ | 25 evaluations · 25 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench SELEX-ZS-AUC: Overall fitness prediction on NABench SELEX assays, Zero-shot AUC | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench SELEX-ZS-CORR: Overall fitness prediction on NABench SELEX assays, Zero-shot Spearman ρ | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench SELEX-ZS-MCC: Overall fitness prediction on NABench SELEX assays, Zero-shot MCC | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench SELEX-ZS-NDCG: Overall fitness prediction on NABench SELEX assays, Zero-shot NDCG | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench ZS-AUC-APTAMER: Fitness prediction on aptamer assays, zero-shot | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench ZS-AUC-ENHANCER: Fitness prediction on enhancer assays, zero-shot | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench ZS-AUC-MRNA: Fitness prediction on mRNA assays, zero-shot | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench ZS-AUC-PROMOTER: Fitness prediction on promoter assays, zero-shot | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench ZS-AUC-RIBOZYME: Fitness prediction on ribozyme assays, zero-shot | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench ZS-AUC-TRNA: Fitness prediction on tRNA assays, zero-shot | 24 evaluations · 24 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench ZS-CORR-APTAMER: Fitness prediction on aptamer assays, zero-shot | 27 evaluations · 27 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench ZS-CORR-ENHANCER: Fitness prediction on enhancer assays, zero-shot | 26 evaluations · 26 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench ZS-CORR-MRNA: Fitness prediction on mRNA assays, zero-shot | 27 evaluations · 27 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench ZS-CORR-PROMOTER: Fitness prediction on promoter assays, zero-shot | 27 evaluations · 27 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench ZS-CORR-RIBOZYME: Fitness prediction on ribozyme assays, zero-shot | 27 evaluations · 27 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NABench ZS-CORR-TRNA: Fitness prediction on tRNA assays, zero-shot | 25 evaluations · 25 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Natural vs artificial microbial genome sequence | 3 evaluations · 9 rows | 3 source-scoped figures | Checked result tables available.Scope and remaining work
|
| non-coding RNA pairwise interaction prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Open Problems label projection CENGEN-BATCH-ACCURACY: Label projection on CeNGEN (split by batch), Accuracy | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection CENGEN-BATCH-F1-MACRO: Label projection on CeNGEN (split by batch), Macro F1 score | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection CENGEN-BATCH-F1: Label projection on CeNGEN (split by batch), F1 score | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection CENGEN-RANDOM-ACCURACY: Label projection on CeNGEN (random split), Accuracy | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection CENGEN-RANDOM-F1-MACRO: Label projection on CeNGEN (random split), Macro F1 score | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection CENGEN-RANDOM-F1: Label projection on CeNGEN (random split), F1 score | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection PANCREAS-BATCH-ACCURACY: Label projection on Pancreas (by batch), Accuracy | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection PANCREAS-BATCH-F1-MACRO: Label projection on Pancreas (by batch), Macro F1 score | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection PANCREAS-BATCH-F1: Label projection on Pancreas (by batch), F1 score | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection PANCREAS-RANDOM-ACCURACY: Label projection on Pancreas (random split), Accuracy | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection PANCREAS-RANDOM-F1-MACRO: Label projection on Pancreas (random split), Macro F1 score | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection PANCREAS-RANDOM-F1: Label projection on Pancreas (random split), F1 score | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection PANCREAS-RANDOM-LABEL-NOISE-ACCURACY: Label projection on Pancreas (random split with label noise), Accuracy | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection PANCREAS-RANDOM-LABEL-NOISE-F1-MACRO: Label projection on Pancreas (random split with label noise), Macro F1 score | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection PANCREAS-RANDOM-LABEL-NOISE-F1: Label projection on Pancreas (random split with label noise), F1 score | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection TABULA-MURIS-SENIS-LUNG-RANDOM-ACCURACY: Label projection on Tabula Muris Senis Lung (random split), Accuracy | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection TABULA-MURIS-SENIS-LUNG-RANDOM-F1-MACRO: Label projection on Tabula Muris Senis Lung (random split), Macro F1 score | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection TABULA-MURIS-SENIS-LUNG-RANDOM-F1: Label projection on Tabula Muris Senis Lung (random split), F1 score | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection ZEBRAFISH-LABS-ACCURACY: Label projection on Zebrafish (by laboratory), Accuracy | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection ZEBRAFISH-LABS-F1-MACRO: Label projection on Zebrafish (by laboratory), Macro F1 score | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection ZEBRAFISH-LABS-F1: Label projection on Zebrafish (by laboratory), F1 score | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection ZEBRAFISH-RANDOM-ACCURACY: Label projection on Zebrafish (random split), Accuracy | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection ZEBRAFISH-RANDOM-F1-MACRO: Label projection on Zebrafish (random split), Macro F1 score | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Open Problems label projection ZEBRAFISH-RANDOM-F1: Label projection on Zebrafish (random split), F1 score | 16 evaluations · 16 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| pathogen detection | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Pathological complete response from inferred tumour composition | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| PBMC cell-type classification | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Perturbation response | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| PerturBench CB-COSINE-RANK: combination prediction on Norman19, Cosine LogFC rank | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PerturBench CB-COSINE: combination prediction on Norman19, Cosine similarity of log fold change | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PerturBench CB-RMSE-RANK: combination prediction on Norman19, RMSE mean rank | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PerturBench CB-RMSE: combination prediction on Norman19, RMSE of the mean | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PerturBench CT-COSINE-RANK: covariate transfer on Srivatsan20, Cosine LogFC rank | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PerturBench CT-COSINE: covariate transfer on Srivatsan20, Cosine similarity of log fold change | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PerturBench CT-RMSE-RANK: covariate transfer on Srivatsan20, RMSE mean rank | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PerturBench CT-RMSE: covariate transfer on Srivatsan20, RMSE of the mean | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PFMBench ANTI-RES: Antibiotic resistance | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PFMBench BINDING-DB: BindingDB | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PFMBench CLONING-CLF: Cloning CLF | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PFMBench DEEPLOC2: DeepLoc2 Multi | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PFMBench DEEPSOL: DeepSol | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PFMBench EC: Enzyme Commission | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PFMBench MAT-PROD: Material production | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PFMBench METAL-ION: Metal ion binding | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PFMBench PDB-BIND: PDBbind | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PFMBench PROTEINGYM-ZS: ProteinGym zero-shot variant effect prediction | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PFMBench SEC-STRUCT: Secondary structure | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PFMBench STABILITY: TAPE_Stability | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Phage / pathogen reads | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Physically valid protein–ligand pose selection | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| polyadenylation site detection | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Prediction of VHH expression from sequence | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Protein design / inverse folding | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| protein function annotation | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| protein localization classification | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| protein variant fitness prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| protein variant-effect classification | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| protein-ligand binding affinity prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| protein-protein binding-site prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| protein-protein interaction prediction | 7 evaluations · 34 rows | 11 source-scoped figures | Checked result tables available.Scope and remaining work
|
| protein-protein interaction prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| protein-small molecule binding-site prediction | 12 evaluations · 45 rows | 12 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Protein–ligand binding affinity prediction | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Protein–ligand binding affinity scoring | 37 evaluations · 82 rows | 9 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Protein–ligand binding energy prediction | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Protein–ligand pose | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Protein–ligand pose prediction | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Protein–ligand pose prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Protein–ligand virtual screening | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ProteinBench AB-ACCURACY-AAR: Accuracy AAR | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench AB-ACCURACY-RMSD: Accuracy RMSD | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench AB-ACCURACY-TM-SCORE: Accuracy TM-score | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench AB-FUNCTIONALITY-BINDING-ENERGY: Functionality Binding Energy | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench AB-RATIONALITY-CLASHES-INNER: Rationality Clashes-inner | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench AB-RATIONALITY-CLASHES-OUTER: Rationality Clashes-outer | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench AB-RATIONALITY-CN-SCORE: Rationality CN-score | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench AB-RATIONALITY-SCRMSD: Rationality scRMSD | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench AB-RATIONALITY-SEQNAT: Rationality SeqNat | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench AB-RATIONALITY-TOTAL-ENERGY: Rationality Total Energy | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench AB-SPECIFICITY-PHR: Specificity PHR | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench AB-SPECIFICITY-SEQSIM-INNER: Specificity SeqSim-inner | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench AB-SPECIFICITY-SEQSIM-OUTER: Specificity SeqSim-outer | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-100-DIVERSITY-MAX-CLUST: length 100, Diversity Max Clust. | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-100-DIVERSITY-PAIRWISE-TM: length 100, Diversity pairwise TM | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-100-NOVELTY-MAX-TM: length 100, Novelty Max TM | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-100-QUALITY-SCRMSD: length 100, Quality scRMSD | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-100-QUALITY-SCTM: length 100, Quality scTM | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-300-DIVERSITY-MAX-CLUST: length 300, Diversity Max Clust. | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-300-DIVERSITY-PAIRWISE-TM: length 300, Diversity pairwise TM | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-300-NOVELTY-MAX-TM: length 300, Novelty Max TM | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-300-QUALITY-SCRMSD: length 300, Quality scRMSD | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-300-QUALITY-SCTM: length 300, Quality scTM | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-50-DIVERSITY-MAX-CLUST: length 50, Diversity Max Clust. | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-50-DIVERSITY-PAIRWISE-TM: length 50, Diversity pairwise TM | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-50-NOVELTY-MAX-TM: length 50, Novelty Max TM | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-50-QUALITY-SCRMSD: length 50, Quality scRMSD | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-50-QUALITY-SCTM: length 50, Quality scTM | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-500-DIVERSITY-MAX-CLUST: length 500, Diversity Max Clust. | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-500-DIVERSITY-PAIRWISE-TM: length 500, Diversity pairwise TM | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-500-NOVELTY-MAX-TM: length 500, Novelty Max TM | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-500-QUALITY-SCRMSD: length 500, Quality scRMSD | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench BB-LENGTH-500-QUALITY-SCTM: length 500, Quality scTM | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench CO-LENGTH-100-DIVERSITY-MAX-CLUST: length 100, Diversity Max Clust. | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench CO-LENGTH-100-NOVELTY-MAX-TM: length 100, Novelty Max TM | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench CO-LENGTH-100-QUALITY-SCRMSD: length 100, Quality scRMSD | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench CO-LENGTH-100-QUALITY-SCTM: length 100, Quality scTM | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench CO-LENGTH-200-DIVERSITY-MAX-CLUST: length 200, Diversity Max Clust. | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench CO-LENGTH-200-NOVELTY-MAX-TM: length 200, Novelty Max TM | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench CO-LENGTH-200-QUALITY-SCRMSD: length 200, Quality scRMSD | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench CO-LENGTH-200-QUALITY-SCTM: length 200, Quality scTM | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench CO-LENGTH-300-DIVERSITY-MAX-CLUST: length 300, Diversity Max Clust. | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench CO-LENGTH-300-NOVELTY-MAX-TM: length 300, Novelty Max TM | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench CO-LENGTH-300-QUALITY-SCRMSD: length 300, Quality scRMSD | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench CO-LENGTH-300-QUALITY-SCTM: length 300, Quality scTM | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench CO-LENGTH-500-DIVERSITY-MAX-CLUST: length 500, Diversity Max Clust. | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench CO-LENGTH-500-NOVELTY-MAX-TM: length 500, Novelty Max TM | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench CO-LENGTH-500-QUALITY-SCRMSD: length 500, Quality scRMSD | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench CO-LENGTH-500-QUALITY-SCTM: length 500, Quality scTM | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench FOLD-ACCURACY-GDT-TS-MEAN: Accuracy GDT-TS (mean) | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench FOLD-ACCURACY-GDT-TS-MEDIAN: Accuracy GDT-TS (median) | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench FOLD-ACCURACY-LDDT-MEAN: Accuracy lDDT (mean) | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench FOLD-ACCURACY-LDDT-MEDIAN: Accuracy lDDT (median) | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench FOLD-ACCURACY-RMSD-MEAN: Accuracy RMSD (mean) | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench FOLD-ACCURACY-RMSD-MEDIAN: Accuracy RMSD (median) | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench FOLD-ACCURACY-TM-SCORE-MEAN: Accuracy TM-score (mean) | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench FOLD-ACCURACY-TM-SCORE-MEDIAN: Accuracy TM-score (median) | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench FOLD-QUALITY-CA-BREAK-MEAN: Quality CA break (%) (mean) | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench FOLD-QUALITY-CA-BREAK-MEDIAN: Quality CA break (%) (median) | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench FOLD-QUALITY-CA-CLASH-MEAN: Quality CA clash (%) (mean) | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench FOLD-QUALITY-CA-CLASH-MEDIAN: Quality CA clash (%) (median) | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench FOLD-QUALITY-PEPBOND-BREAK-MEAN: Quality PepBond break (%) (mean) | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench FOLD-QUALITY-PEPBOND-BREAK-MEDIAN: Quality PepBond break (%) (median) | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench IF-DE-NOVO-BACKBONES-BASED-SEQUENCE-DESIGN-LENGTH-100-PLDDT: De novo backbones based sequence design, length 100 pLDDT | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench IF-DE-NOVO-BACKBONES-BASED-SEQUENCE-DESIGN-LENGTH-100-SCTM: De novo backbones based sequence design, length 100 scTM | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench IF-DE-NOVO-BACKBONES-BASED-SEQUENCE-DESIGN-LENGTH-200-PLDDT: De novo backbones based sequence design, length 200 pLDDT | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench IF-DE-NOVO-BACKBONES-BASED-SEQUENCE-DESIGN-LENGTH-200-SCTM: De novo backbones based sequence design, length 200 scTM | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench IF-DE-NOVO-BACKBONES-BASED-SEQUENCE-DESIGN-LENGTH-300-PLDDT: De novo backbones based sequence design, length 300 pLDDT | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench IF-DE-NOVO-BACKBONES-BASED-SEQUENCE-DESIGN-LENGTH-300-SCTM: De novo backbones based sequence design, length 300 scTM | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench IF-DE-NOVO-BACKBONES-BASED-SEQUENCE-DESIGN-LENGTH-400-PLDDT: De novo backbones based sequence design, length 400 pLDDT | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench IF-DE-NOVO-BACKBONES-BASED-SEQUENCE-DESIGN-LENGTH-400-SCTM: De novo backbones based sequence design, length 400 scTM | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench IF-DE-NOVO-BACKBONES-BASED-SEQUENCE-DESIGN-LENGTH-500-PLDDT: De novo backbones based sequence design, length 500 pLDDT | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench IF-DE-NOVO-BACKBONES-BASED-SEQUENCE-DESIGN-LENGTH-500-SCTM: De novo backbones based sequence design, length 500 scTM | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench IF-FITTING-EVOLUTION-DISTRIBUTION-CAMEO-AAR: Fitting Evolution Distribution, CAMEO AAR | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench IF-FITTING-EVOLUTION-DISTRIBUTION-CASP-AAR: Fitting Evolution Distribution, CASP AAR | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-100-DIVERSITY-MAX-CLUST: length 100, Diversity Max Clust. | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-100-DIVERSITY-PAIRWISE-TM: length 100, Diversity pairwise TM | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-100-NOVELTY-MAX-TM: length 100, Novelty Max TM | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-100-QUALITY-PLDDT: length 100, Quality pLDDT | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-100-QUALITY-PPL: length 100, Quality ppl | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-200-DIVERSITY-MAX-CLUST: length 200, Diversity Max Clust. | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-200-DIVERSITY-PAIRWISE-TM: length 200, Diversity pairwise TM | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-200-NOVELTY-MAX-TM: length 200, Novelty Max TM | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-200-QUALITY-PLDDT: length 200, Quality pLDDT | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-200-QUALITY-PPL: length 200, Quality ppl | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-300-DIVERSITY-MAX-CLUST: length 300, Diversity Max Clust. | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-300-DIVERSITY-PAIRWISE-TM: length 300, Diversity pairwise TM | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-300-NOVELTY-MAX-TM: length 300, Novelty Max TM | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-300-QUALITY-PLDDT: length 300, Quality pLDDT | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-300-QUALITY-PPL: length 300, Quality ppl | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-500-DIVERSITY-MAX-CLUST: length 500, Diversity Max Clust. | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-500-DIVERSITY-PAIRWISE-TM: length 500, Diversity pairwise TM | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-500-NOVELTY-MAX-TM: length 500, Novelty Max TM | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-500-QUALITY-PLDDT: length 500, Quality pLDDT | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinBench SEQ-LENGTH-500-QUALITY-PPL: length 500, Quality ppl | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym mutation effects | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| ProteinGym SUP-SUB-MSE-AVG: Supervised substitutions, average over splits, MSE | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym SUP-SUB-MSE-CONTIG: Supervised substitutions, contiguous split, MSE | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym SUP-SUB-MSE-MOD: Supervised substitutions, modulo split, MSE | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym SUP-SUB-MSE-RAND: Supervised substitutions, random split, MSE | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym SUP-SUB-SPEARMAN-AVG: Supervised substitutions, average over splits, Spearman | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym SUP-SUB-SPEARMAN-CONTIG: Supervised substitutions, contiguous split, Spearman | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym SUP-SUB-SPEARMAN-MOD: Supervised substitutions, modulo split, Spearman | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym SUP-SUB-SPEARMAN-RAND: Supervised substitutions, random split, Spearman | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym ZS-INDEL-AUC: Zero-shot indels, all assays, AUC | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym ZS-INDEL-SPEARMAN-ALL: Zero-shot indels, all assays, Spearman | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym ZS-INDEL-SPEARMAN-DESIGNED: Zero-shot indels, designed or natural assays, Spearman | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym ZS-INDEL-SPEARMAN-LIBRARY: Zero-shot indels, library assays, Spearman | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym ZS-SUB-AUC: Zero-shot substitutions, AUC | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym ZS-SUB-MCC: Zero-shot substitutions, MCC | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym ZS-SUB-NDCG: Zero-shot substitutions, NDCG@10% | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym ZS-SUB-RECALL: Zero-shot substitutions, top 10% recall | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym ZS-SUB-SPEARMAN: Zero-shot substitutions, Spearman | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| regulatory element identification | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| regulatory sequence classification | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| regulatory-variant scoring | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RNA compound-binding site prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RNA secondary structure | 40 evaluations · 160 rows | 16 source-scoped figures | Checked result tables available. |
| RNA secondary structure | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RNA secondary structure | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RNA secondary structure | 40 evaluations · 160 rows | 16 source-scoped figures | Checked result tables available.Scope and remaining work
|
| RNA secondary-structure prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RNA sequence design | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RNA splice-site mapping | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| RNA tertiary structure | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| RNA-small-molecule binding-site prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Runtime of a binder design run | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Simulated metagenome virus-taxon retrieval | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Simulated prophage-contig detection | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Small-molecule affinity | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Strain-level abundance quantification | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Survival prognosis from pretreatment bulk RNA-seq | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| TAPE Contact Prediction | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available. |
| TAPE Fluorescence | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available. |
| TAPE Remote Homology Detection | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available. |
| TAPE Secondary Structure | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available. |
| TAPE Stability | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available. |
| TDC ADMET benchmark group TDC-AMES: Toxicity: TDC.AMES | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-AQSOL: Absorption: TDC.AqSol | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-BBB: Distribution: TDC.BBB | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-BIOAV: Absorption: TDC.Bioav | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-CACO2: Absorption: TDC.Caco2 | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-CL-HEPA: Excretion: TDC.CL-Hepa | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-CL-MICRO: Excretion: TDC.CL-Micro | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-CYP2C9-INHIBITION: Metabolism: TDC.CYP2C9 Inhibition | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-CYP2C9-SUBSTRATE: Metabolism: TDC.CYP2C9 Substrate | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-CYP2D6-INHIBITION: Metabolism: TDC.CYP2D6 Inhibition | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-CYP2D6-SUBSTRATE: Metabolism: TDC.CYP2D6 Substrate | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-CYP3A4-INHIBITION: Metabolism: TDC.CYP3A4 Inhibition | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-CYP3A4-SUBSTRATE: Metabolism: TDC.CYP3A4 Substrate | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-DILI: Toxicity: TDC.DILI | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-HALF-LIFE: Excretion: TDC.Half Life | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-HERG: Toxicity: TDC.hERG | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-HIA: Absorption: TDC.HIA | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-LD50: Toxicity: TDC.LD50 | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-LIPO: Absorption: TDC.Lipo | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-PGP: Absorption: TDC.Pgp | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-PPBR: Distribution: TDC.PPBR | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TDC ADMET benchmark group TDC-VD: Distribution: TDC.VDss | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| transcription-factor DNA binding-site prediction | 6 evaluations · 12 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Translation / RNA stability | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| translation-efficiency prediction | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Treatment benefit (predictive biomarker) from bulk RNA-seq | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| unseen-species genus classification | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| vaccine-antigen candidate prediction | 4 evaluations · 22 rows | 7 source-scoped figures | Checked result tables available.Scope and remaining work
|
| viral sequence detection | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot fitness prediction on RNAGym ncRNA DMS assays | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Zero-shot substitution mutation effects: stability | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot variant effect prediction | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
Protocols
1567 pages · 1536 with results · 326 with charts.
| Page | Evaluations and metric rows | Charts | Collection status |
|---|---|---|---|
| AAV low-vs-high (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| AAV two-vs-many (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ABCA4 deep-intronic variants: classification against mini- or midigene splicing results (Riepe et al. Table 4) | 9 evaluations · 99 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ABCA4 noncanonical splice-site variants: classification against mini- or midigene splicing results (Riepe et al. Table 3) | 11 evaluations · 121 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Abdelaal et al. 2019 inter-dataset brain comparison: VISp/ALM/MTG, 34-population annotation (Figure S10 Panel B) | 9 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Abdelaal et al. 2019 intra-dataset 5-fold CV: Baron Human pancreatic dataset | 4 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Acetyltransferase dataset stability ranking, Spearman correlation (Chu et al. 2024 Table 1) | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ACMG five-category CNV pathogenicity classification against expert labels (Zhang et al. Table 3) | 5 evaluations · 35 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Acute leukaemia whole RNA-seq fusion detection against conventional diagnostics (Kim et al. 2026) | 1 evaluation · 83 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Adamson et al. 2016 Perturb-seq, K562 CRISPRi single perturbations: unseen-perturbation expression prediction (Csendes et al. 2025 Supplementary Table 2) | 15 evaluations · 88 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Adamson: expression prediction for unseen single perturbations (Ahlmann-Eltze et al. 2025 Fig. 2a and Extended Data Fig. 8a) | 7 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Adaptyv EGFR competition BLI affinity | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Adaptyv EGFR competition BLI binding screen | 4 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Adaptyv EGFR competition cell-free expression rate | 5 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| African-ancestry LCL caQTL classification (AlphaGenome paper) | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| African-ancestry LCL caQTL effect-size prediction (AlphaGenome paper) | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| All fusions, conventional RNA-seq of haematologic cell lines, consensus truth (Tamura et al. 2026 Supplementary Table 3) | 12 evaluations · 72 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| All fusions, targeted RNA-seq of haematologic cell lines, consensus truth (Tamura et al. 2026 Supplementary Table 3) | 12 evaluations · 72 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Allelic reporter effect correlation in HeLa (Manzo et al. 2025 Table 1) | 24 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Allelic reporter effect correlation in HepG2 (Manzo et al. 2025 Table 1) | 24 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Allelic reporter effect correlation in K562 (Manzo et al. 2025 Table 1) | 24 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Allelic reporter effect correlation in NPC (Manzo et al. 2025 Table 1) | 24 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| AlphaBind PEM held-out antigen, pairwise accuracy | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| AlphaBind PP489 held-out antigen, pairwise accuracy | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| AlphaBind TRA held-out antigen, pairwise accuracy | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| AlphaBind VHH72 held-out antigen, pairwise accuracy | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| AlphaProteo best per-target binder affinity by HTRF | 25 evaluations · 25 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| AlphaProteo expression and HTRF confirmation funnel for yeast-display hits | 28 evaluations · 28 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| AlphaProteo yeast-display binding screen, hit at binding signal above 0.2 | 26 evaluations · 26 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| AlphaProteo yeast-display binding screen, hit at binding signal above 1.3 (IL-17A) | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Alternative polyadenylation coverage ratios (AlphaGenome paper) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| AML tumour somatic SNVs, WGS (Wang et al. 2020 Table S1) | 15 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Amylase by mutation count (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Amylase one-to-many (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Annotation of a held-out batch after fine-tuning (HyCell report) | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Annotation transfer with 15-nearest neighbours (HyCell report) | 16 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Annotation transfer with logistic regression (HyCell report) | 16 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Apparent dissociation constant of a selected minibinder design by biolayer interferometry | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Apparent dissociation constant of a selected VHH design by biolayer interferometry | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Arch retrieval (DGEB) (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ArchiveII (RNA secondary structure) | 10 evaluations · 40 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| AssayBench-Loop adaptive hit discovery: 10 rounds of 100 genes on 20 held-out CRISPR screens | 53 evaluations · 530 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| AssayBench: rank 100 candidate genes for a described CRISPR screen | 48 evaluations · 144 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ATAC prediction on held-out peaks (AlphaGenome paper) | 2 evaluations · 6 rows | 3 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ATAC track prediction at 128 bp (AlphaGenome paper) | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ATAC track prediction at 32 bp (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Author MFASS splice-disruption prediction (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| AVI feature ablation, ClinVar column, AUPRC (AlphaGenome Atlas Table S2) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| AVI feature ablation, ncVar column, AUPRC (AlphaGenome Atlas Table S2) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| AVI feature ablation, SGE column, AUPRC (AlphaGenome Atlas Table S2) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| AVI feature ablation, TraitGym Complex column, AUPRC (AlphaGenome Atlas Table S2) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| AVI feature ablation, TraitGym Mendelian column, AUPRC (AlphaGenome Atlas Table S2) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| B-cell to plasma-cell pseudotime ordering, all cells (HyCell report) | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| B-cell to plasma-cell pseudotime ordering, donor mean (HyCell report) | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BacBench antibiotic resistance, binary linear probe AUPRC | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BacBench antibiotic resistance, binary linear probe AUROC | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BacBench antibiotic resistance, MIC regression Pearson correlation | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BacBench antibiotic resistance, MIC regression R squared | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BacBench essential gene prediction, linear probe AUPRC | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BacBench essential gene prediction, linear probe AUROC | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BacBench operon identification, zero-shot AUPRC | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BacBench operon identification, zero-shot AUROC | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BacBench phenotypic trait prediction, linear probe AUPRC | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BacBench phenotypic trait prediction, linear probe AUROC | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BacBench protein-protein interaction, linear probe AUPRC | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BacBench protein-protein interaction, linear probe AUROC | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BacBench protein-protein interaction, zero-shot AUPRC | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BacBench protein-protein interaction, zero-shot AUROC | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BacBench strain clustering, adjusted Rand index | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BacBench strain clustering, average silhouette width | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BacBench strain clustering, normalised mutual information | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Base-resolution RNA-seq prediction (AlphaGenome paper) | 2 evaluations · 4 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 2 · BF | 12 evaluations · 24 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 2 · BFC | 12 evaluations · 24 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 2 · CY | 12 evaluations · 24 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 2 · LI | 12 evaluations · 24 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 2 · LL | 12 evaluations · 24 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 2 · TF | 12 evaluations · 24 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 4 · GSD | 12 evaluations · 48 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 4 · HSC | 12 evaluations · 48 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 4 · mCAD | 12 evaluations · 48 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 4 · VSC | 12 evaluations · 36 rows | 3 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · hESC · Cell-type specific ChIP-Seq network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · hESC · Cell-type specific ChIP-Seq network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · hESC · Non-specific ChIP-Seq network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · hESC · Non-specific ChIP-Seq network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · hESC · STRING network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · hESC · STRING network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · hHep · Cell-type specific ChIP-Seq network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · hHep · Cell-type specific ChIP-Seq network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · hHep · Non-specific ChIP-Seq network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · hHep · Non-specific ChIP-Seq network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · hHep · STRING network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · hHep · STRING network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mDC · Cell-type specific ChIP-Seq network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mDC · Cell-type specific ChIP-Seq network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mDC · Non-specific ChIP-Seq network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mDC · Non-specific ChIP-Seq network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mDC · STRING network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mDC · STRING network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mESC · Cell-type specific ChIP-Seq network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mESC · Cell-type specific ChIP-Seq network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mESC · log/gof network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mESC · log/gof network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mESC · Non-specific ChIP-Seq network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mESC · Non-specific ChIP-Seq network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mESC · STRING network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mESC · STRING network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mHSC-E · Cell-type specific ChIP-Seq network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mHSC-E · Cell-type specific ChIP-Seq network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mHSC-E · Non-specific ChIP-Seq network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mHSC-E · Non-specific ChIP-Seq network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mHSC-E · STRING network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mHSC-E · STRING network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · MHSC-GM · Cell-type specific ChIP-Seq network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · MHSC-GM · Cell-type specific ChIP-Seq network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · MHSC-GM · Non-specific ChIP-Seq network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · MHSC-GM · Non-specific ChIP-Seq network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · MHSC-GM · STRING network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · MHSC-GM · STRING network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mHSC-L · Cell-type specific ChIP-Seq network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mHSC-L · Cell-type specific ChIP-Seq network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mHSC-L · Non-specific ChIP-Seq network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mHSC-L · Non-specific ChIP-Seq network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mHSC-L · STRING network, TFs+1000 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BEELINE 2020 Figure 5 · mHSC-L · STRING network, TFs+500 genes | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BenchBench-Cloning aggregate score over all 65 tasks | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BenchBench-Cloning construct design, per task: attempts passed out of 5, deterministic grading only | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BenchBench-Cloning construct design, per task: attempts passed out of 5, deterministic grading with a rubric model judge | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BenchBench-Cloning construct design: single-attempt pass rate over 15 tasks | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BenchBench-Cloning protocol development: pass@10 over 50 tasks | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BenchBench-Cloning protocol development: pass@5 over 50 tasks | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BenchBench-Cloning protocol development: single-attempt pass rate over 50 tasks | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BenchBench-Cloning protocol development: tasks solved at least once in the ten recorded attempts, out of 50 | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BenchBench-Cloning protocol development: tasks solved in every one of the ten recorded attempts, out of 50 | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Benet-Pages BRCA1/BRCA2 VUS reclassification: ACMG/AMP + SVI step (t2) | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Benet-Pages BRCA1/BRCA2 VUS reclassification: ENIGMA VCEP step (t3) | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Bennett VHH computational success rate under an AlphaFold3 filter | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Bennett VHH computational success rate under the fine-tuned RoseTTAFold2 filter | 18 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Bennett VHH design, E. coli expression and single-concentration SPR screen of 96 designs | 3 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Bennett VHH design, yeast surface display screen of 9,000 designs with SPR confirmation | 3 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BERTax Closely related dataset: taxonomic classification at superkingdom and phylum (Mock et al. 2022) | 9 evaluations · 54 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BERTax Distantly related dataset: taxonomic classification at superkingdom and phylum (Mock et al. 2022) | 9 evaluations · 72 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BERTax Final model dataset: taxonomic classification at superkingdom and phylum, and genus (Mock et al. 2022) | 9 evaluations · 27 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Best DockQ against sampling depth on cognate nanobody-antigen complexes | 4 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BF16 path minus reference sampler in scTM at fixed diversity (HyInv report) | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Bgl3 dataset stability ranking, Spearman correlation (Chu et al. 2024 Table 1) | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BglB dataset stability ranking, Spearman correlation (Chu et al. 2024 Table 1) | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BindCraft best per-target binder affinity | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BindCraft experimental success rate averaged over its 12 benchmark targets | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BindCraft per-target binding screen, hit where a binding signal was observed | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BioDiscoveryAgent 1-gene perturbation design: hit ratio after 5 rounds of 128 genes | 120 evaluations · 240 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BioML-bench drug discovery domain: agent leaderboard percentile over 9 tasks | 10 evaluations · 34 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BioML-bench protein engineering domain: agent leaderboard percentile over 6 tasks | 10 evaluations · 34 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BioML-bench single cell omics domain: agent leaderboard percentile over 5 tasks | 10 evaluations · 44 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Blood single-cell to isoform, direction accuracy for COVID-19 against healthy draws, top 5% of genes | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Blood single-cell to isoform, direction accuracy for day 0 to day 14 change, top 5% of genes | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| bpRNA-TS0 (RNA secondary structure) | 10 evaluations · 40 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| BRCA1 BayesDel evidence calibration | 1 evaluation · 15 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BRCA1 functional truth set, binary in silico calls (Cubuk et al. 2021) | 84 evaluations · 247 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BRCA1 generic BayesDel threshold evidence-code assignment | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BRCA1 MAVE LoF discrimination at the PP3 threshold (Ramadane-Morchadi et al. 2025 Table 2) | 6 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BRCA1 MAVE PP3/BP4 evidence strength by score threshold (Ramadane-Morchadi et al. 2025 Table 1) | 8 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BRCA1 saturation genome editing, synonymous and intronic SNVs: transcriptome-normalised sensitivity at a 10% background call rate (Smith and Kitzman Table S2) | 8 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BRCA2 BayesDel evidence calibration | 1 evaluation · 15 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BRCA2 functional truth set, binary in silico calls (Cubuk et al. 2021) | 84 evaluations · 226 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| BRCA2 generic BayesDel threshold evidence-code assignment | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Breast cancer pCR, ER+/HER2- external cohorts, AUC of a model fitted on TransNEO | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Breast cancer pCR, HER2+ external cohorts, AUC of a model fitted on TransNEO | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CA-lDDT of designed sequences under ESMFold2 (HyInv report) | 60 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CACHE #3 merged Round 1 library prediction per workflow (Herasymenko et al. 2026 Table S8) | 19 evaluations · 171 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CACHE #3 Round 1 own-selection outcome per workflow (Herasymenko et al. 2026 Table S8) | 23 evaluations · 161 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CAFA3 BPO all organisms; type1 no-knowledge; mode1 · CAFA3 final benchmark; BPO; all; type1; mode1 | 146 evaluations · 146 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| CAFA3 CCO all organisms; type1 no-knowledge; mode1 · CAFA3 final benchmark; CCO; all; type1; mode1 | 146 evaluations · 146 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| CAFA3 MFO all organisms; type1 no-knowledge; mode1 · CAFA3 final benchmark; MFO; all; type1; mode1 | 146 evaluations · 146 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| CAGE track prediction at 128 bp (AlphaGenome paper) | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| CAGE track prediction at 32 bp (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| CAGI5 saturation MPRA variant effect correlation, HepG2 (Tang et al. 2025 Table 1) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CAGI5 saturation MPRA variant effect correlation, K562 (Tang et al. 2025 Table 1) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CAMI II marine genome binning; pooled short-read gold-standard assembly; circular elements excluded · marmgCAMI2_short_read_pooled_gold_standard_assembly | 16 evaluations · 256 rows | 16 source-scoped figures | Checked result tables available.Scope and remaining work
|
| CAPRI round 61 predictor; submitted model 1; T312.1 · CAPRI round 61 T312.1 | 25 evaluations · 100 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| CAPRI round 61 predictor; submitted model 1; T314.1 · CAPRI round 61 T314.1 | 25 evaluations · 100 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| CAPRI round 61 predictor; submitted model 1; T315.1 · CAPRI round 61 T315.1 | 25 evaluations · 100 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| CAPRI round 61 predictor; submitted model 1; T316.1 · CAPRI round 61 T316.1 | 25 evaluations · 100 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Carrier plasma protein levels for rare splice-region variants, UK Biobank (SpliceAI2 paper, Pearson) | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CASF-2016 docking (Protein–ligand binding affinity scoring) | 9 evaluations · 27 rows | 3 source-scoped figures | Checked result tables available.Scope and remaining work
|
| CASF-2016 ranking (Protein–ligand binding affinity scoring) | 9 evaluations · 27 rows | 3 source-scoped figures | Checked result tables available.Scope and remaining work
|
| CASF-2016 scoring (Protein–ligand binding affinity scoring) | 9 evaluations · 9 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| CASP16 affinity challenge, Boltz-2 against the top-ranked participants | 10 evaluations · 90 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CASP16 protein domain; first submitted model; T1201-D1 · CASP16 T1201-D1 | 90 evaluations · 270 rows | 6 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Causal-gene rank in 152 KGD trio-family exomes across parameter protocols (Yuan et al. 2024 Table 1) | 13 evaluations · 91 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Causal-gene rank in 209 in-house exomes, default singleton runs (Yuan et al. 2022 SM Table 3) | 11 evaluations · 77 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Causal-gene rank in 305 DDD exomes, default singleton runs (Yuan et al. 2022 SM Table 3) | 11 evaluations · 77 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Causal-gene rank in 305 DDD trio-family exomes across parameter protocols (Yuan et al. 2024 Table 1) | 13 evaluations · 91 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation | 9 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CCGA substudy 1 validation set: cancer signal origin accuracy among jointly detected cancers | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CCGA substudy 1 validation set: cancer signal sensitivity at 98% specificity | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CD4 T-cell split against sequencing chemistry, NMI (HyCell report) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ceiling-normalised comparison, EditJumps, two families, 200 references: Covariance (% of ceiling) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ceiling-normalised comparison, EditJumps, two families, 200 references: MIP (% of ceiling) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ceiling-normalised comparison, EditJumps, two families, 200 references: Pairwise Distance‡ | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ceiling-normalised comparison, EditJumps, two families, 200 references: Positional JS† (× floor) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ceiling-normalised comparison, EvoFlows published values, six families: Covariance (% of ceiling) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ceiling-normalised comparison, EvoFlows published values, six families: MIP (% of ceiling) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ceiling-normalised comparison, EvoFlows published values, six families: Pairwise Distance‡ | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ceiling-normalised comparison, EvoFlows published values, six families: Positional JS† (× floor) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22) | 17 evaluations · 85 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21) | 33 evaluations · 165 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Cell-type difference in chromatin contact-map prediction (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| cfMethyl-Seq random-split four-cancer detection | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CGC missense oncogenicity, all genes (Lee 2026, OncoCal tool_performance.tsv) | 49 evaluations · 98 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CGC missense oncogenicity, oncogenes (gain of function) (Lee 2026, OncoCal tool_performance.tsv) | 49 evaluations · 98 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CGC missense oncogenicity, tumour suppressors (loss of function) (Lee 2026, OncoCal tool_performance.tsv) | 49 evaluations · 98 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 continually pretrained clustering, ATAA | 3 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 continually pretrained clustering, BC | 4 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 continually pretrained clustering, BMMC | 3 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 continually pretrained clustering, HS | 3 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 continually pretrained clustering, ME | 4 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 continually pretrained clustering, MH | 4 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 genetic perturbation prediction, Adamson | 4 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 genetic perturbation prediction, Norman | 4 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 genetic perturbation prediction, Replogle | 4 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 supervised cell type annotation, ATAA | 5 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 supervised cell type annotation, BMMC | 5 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 supervised cell type annotation, HS | 5 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 supervised cell type annotation, SEAAD | 6 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 zero-shot cell type and spatial domain clustering, ATAA | 5 evaluations · 15 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 zero-shot cell type and spatial domain clustering, BC | 6 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 zero-shot cell type and spatial domain clustering, BMMC | 5 evaluations · 15 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 zero-shot cell type and spatial domain clustering, HS | 5 evaluations · 15 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 zero-shot cell type and spatial domain clustering, ME | 6 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 zero-shot cell type and spatial domain clustering, MH | 6 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 zero-shot clustering with k-means, ATAA | 1 evaluation · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 zero-shot clustering with k-means, BC | 1 evaluation · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 zero-shot clustering with k-means, BMMC | 1 evaluation · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 zero-shot clustering with k-means, HS | 1 evaluation · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 zero-shot clustering with k-means, ME | 1 evaluation · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Chen et al. 2026 zero-shot clustering with k-means, MH | 1 evaluation · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| chromatin contact-map prediction (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| CIViC evidence-direction retrieval, March 2026 | 3 evaluations · 162 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CIViC-Fact v3 within-linked-publication passage retrieval, post-cutoff cohort | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Clair3 GPU workflow stage runtimes on HG003 ONT and PacBio WGS (Zheng et al. 2026 Supplementary Table 1) | 2 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Clathrin independent test: selected-embedding classifiers (clathrin protein classification) | 13 evaluations · 78 rows | 6 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ClinVar in-frame indel pathogenicity, ROC-AUC (Brandes et al. 2023 Fig. 6b, Supplementary Table 2) | 16 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClinVar missense pathogenicity, ESM1b head to head with one other method on the variants both score (Brandes et al. 2023 Fig. 2g,h, Supplementary Table 2) | 90 evaluations · 180 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClinVar missense pathogenicity, ESM1b versus EVE on variants scored by both (Brandes et al. 2023 Fig. 2b, Results text) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| ClinVar missense pathogenicity, variants scored by all 19 eligible methods (Brandes et al. 2023 Fig. 2e-f, Supplementary Table 2) | 19 evaluations · 38 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClinVar pathogenic versus benign classification from likelihood ratios, AUROC by variant class | 60 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClinVar pathogenic versus benign SNVs by VEP consequence, AUPRC (AlphaGenome Atlas) | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClinVar pathogenic versus benign SNVs within variant type, AUROC (Lu et al. 2025) | 132 evaluations · 132 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClinVar pathogenic vs benign missense, AUPRC (GPN-Star Supplementary Table 3) | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClinVar Pathogenic vs gnomAD common missense, AUROC (GPN-MSA Supplementary Table 4) | 17 evaluations · 34 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClinVar stop-gain pathogenicity by NMD status, ROC-AUC (Brandes et al. 2023 Fig. 6d, Supplementary Table 2) | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CLL tumour somatic indels, WGS (Wang et al. 2020 Table S2) | 12 evaluations · 48 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CLL tumour somatic SNVs, WGS (Wang et al. 2020 Table S1) | 15 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClusPro BM5 Bound antibody top10 | 1 evaluation · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClusPro BM5 Bound antibody top30 | 1 evaluation · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClusPro BM5 difficult aggregate top10 | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClusPro BM5 difficult aggregate top30 | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClusPro BM5 easy aggregate top10 | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClusPro BM5 easy aggregate top30 | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClusPro BM5 Enzyme top10 | 1 evaluation · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClusPro BM5 Enzyme top30 | 1 evaluation · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClusPro BM5 intermediate aggregate top10 | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClusPro BM5 intermediate aggregate top30 | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClusPro BM5 Others top10 | 1 evaluation · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClusPro BM5 Others top30 | 1 evaluation · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClusPro BM5 Total top10 | 1 evaluation · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClusPro BM5 Total top30 | 1 evaluation · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClusPro BM5 Unbound antibody top10 | 1 evaluation · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ClusPro BM5 Unbound antibody top30 | 1 evaluation · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CNV calls returned to clinical experts per caller after filtering, Solve-RD exome reanalysis (Demidov et al. 2024 Table 1, Supplementary Table 4) | 3 evaluations · 63 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Co-folding time per compound on five DEKOIS 2.0 targets (Shen et al. 2025 Table 5) | 6 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| COACH420, trained on CHEN11 (protein-small molecule binding-site prediction) | 3 evaluations · 12 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| COLO829 cell line somatic indels, WGS (Wang et al. 2020 Table S2) | 12 evaluations · 48 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| COLO829 cell line somatic SNVs, WGS (Wang et al. 2020 Table S1) | 15 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| COLO829 tumour-only, indels, AUPRC (Krishnamachari et al. 2026 Supplementary Table 1) | 9 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| COLO829 tumour-only, SNVs, AUPRC (Krishnamachari et al. 2026 Supplementary Table 1) | 9 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Combination phenotype prediction from small training sets: test RMSE at fixed average gene frequency | 1 evaluation · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Combined K562 CRISPR training pairs, weighted metrics (Gschwind et al. 2026 Supplementary Table 3) | 6 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Composite score S (HyCell report) | 96 evaluations · 96 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Contacts, CASP14 (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Contacts, CASP15 (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Contacts, ProteinNet (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Coriell virtual gene-panel CNV precision by exon count and length (De La Vega et al. Table 1) | 2 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Coronary smooth-muscle caQTL effect-size prediction (AlphaGenome paper) | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| COSMIC frequent vs gnomAD common missense, AUPRC (GPN-MSA Supplementary Table 4) | 17 evaluations · 34 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| COSMIC frequent vs gnomAD common missense, AUPRC (GPN-Star Supplementary Table 3) | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Covariance agreement between natural homologs, 100 references | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Covariance agreement between natural homologs, 20 references | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Covariance agreement between natural homologs, 800 references | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CPPC original Challenge 1 final four-knockout prediction score | 20 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CPPC original Challenge 2 prospective target ranking score | 20 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CPPC prospective nomination of desired T-cell states | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CPPC reimplemented best-model Challenge 2 score | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| CPPC screen-1 held-out knockout cell-state proportions | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Cross-atlas annotation transfer, HLCA to Tabula Sapiens, 14 shared cell types (Wu et al. 2025 Table S3) | 23 evaluations · 46 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Cross-atlas annotation transfer, Tabula Sapiens to HLCA, 14 shared cell types (Wu et al. 2025 Table S2) | 23 evaluations · 46 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Cryptic splice site activation by rare GT/AG-creating SNVs, GTEx WGS and RNA-seq (SpliceAI2 paper, auPRC) | 5 evaluations · 17 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Cryptic splice site activation by rare GT/AG-creating variants in Genomics England blood RNA-seq (SpliceAI2 paper, auPRC) | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Cryptic splice site usage among RNA-seq-confirmed GT/AG-creating SNVs, GTEx (SpliceAI2 paper, Spearman) | 4 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Cyclic peptide computational pass rate under cyclisation and TorchScore confidence | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Database storage and classification speed on ONT data, main database (Peres da Silva et al. 2024) | 6 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Davis drug-target affinity, DeepDTA holdout fold | 16 evaluations · 32 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Decoded against counted fold change, plasma against naive B (HyCell report) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DecoNFlow RRBS-CL tumour-fraction limit of detection | 5 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DecoNFlow RRBS-TT tumour-fraction limit of detection | 10 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DecoNFlow WGBS-TT tumour-fraction limit of detection | 10 evaluations · 50 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Deep intronic and synonymous variants splicing-based classification (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DeepProtein beta-lactamase (PEER): GPU Memory (GB) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein beta-lactamase (PEER): MAE ↓ | 17 evaluations · 17 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein beta-lactamase (PEER): Time (hour) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein beta-lactamase (PEER): ρ ↑ | 17 evaluations · 17 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Binary localization (PEER): Averaged F1 ↑ | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Binary localization (PEER): GPU Memory (GB) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Binary localization (PEER): PR-AUC ↑ | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Binary localization (PEER): Time (hour) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein CRISPR-Leenay repair outcome: GPU Memory (GB) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein CRISPR-Leenay repair outcome: MAE ↓ | 11 evaluations · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein CRISPR-Leenay repair outcome: R2 ↑ | 11 evaluations · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein CRISPR-Leenay repair outcome: Time (hour) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Fluorescence (TAPE): GPU Memory (GB) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Fluorescence (TAPE): MAE ↓ | 17 evaluations · 17 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Fluorescence (TAPE): Time (hour) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Fluorescence (TAPE): ρ ↑ | 17 evaluations · 17 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Fold classification (TAPE): Acc ↑ | 9 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Fold classification (TAPE): Averaged F1 ↑ | 9 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Fold classification (TAPE): GPU Memory (GB) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Fold classification (TAPE): Time (hour) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Human PPI (PEER): Averaged F1 ↑ | 11 evaluations · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Human PPI (PEER): GPU Memory (GB) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Human PPI (PEER): PR-AUC ↑ | 11 evaluations · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Human PPI (PEER): Time (hour) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein IEDB epitope prediction: Averaged F1 ↑ | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein IEDB epitope prediction: ROC-AUC ↑ | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein PDB-Jespersen epitope prediction: Averaged F1 ↑ | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein PDB-Jespersen epitope prediction: ROC-AUC ↑ | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein PPI affinity (PEER): GPU Memory (GB) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein PPI affinity (PEER): MAE ↓ | 11 evaluations · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein PPI affinity (PEER): R2 ↑ | 11 evaluations · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein PPI affinity (PEER): Time (hour) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein SAbDab-Chen antibody developability: GPU Memory (GB) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein SAbDab-Chen antibody developability: MAE ↓ | 11 evaluations · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein SAbDab-Chen antibody developability: R2 ↑ | 11 evaluations · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein SAbDab-Chen antibody developability: Time (hour) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein SAbDab-Liberis paratope prediction: Averaged F1 ↑ | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein SAbDab-Liberis paratope prediction: ROC-AUC ↑ | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Secondary structure prediction (TAPE): Acc ↑ | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Secondary structure prediction (TAPE): Averaged F1 ↑ | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Solubility (PEER): Averaged F1 ↑ | 17 evaluations · 17 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Solubility (PEER): GPU Memory (GB) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Solubility (PEER): PR-AUC ↑ | 17 evaluations · 17 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Solubility (PEER): Time (hour) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Stability (TAPE): GPU Memory (GB) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Stability (TAPE): MAE ↓ | 17 evaluations · 17 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Stability (TAPE): Time (hour) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Stability (TAPE): ρ ↑ | 17 evaluations · 17 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Subcellular localization (PEER): Acc ↑ | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Subcellular localization (PEER): Averaged F1 ↑ | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Subcellular localization (PEER): GPU Memory (GB) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Subcellular localization (PEER): Time (hour) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein TAP antibody developability: GPU Memory (GB) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein TAP antibody developability: MAE ↓ | 11 evaluations · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein TAP antibody developability: R2 ↑ | 11 evaluations · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein TAP antibody developability: Time (hour) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Yeast PPI (PEER): Averaged F1 ↑ | 11 evaluations · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Yeast PPI (PEER): GPU Memory (GB) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Yeast PPI (PEER): PR-AUC ↑ | 11 evaluations · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepProtein Yeast PPI (PEER): Time (hour) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepRVAT rare variant association testing, replicated genes (GPN-Star Fig. 2j) | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepRVAT rare variant association testing, significant genes (GPN-Star Fig. 2j) | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DeepVariant execution on CPU and GPU cloud and DGX machines (O'Connell et al. 2023 Table 1) | 11 evaluations · 42 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DEKOIS 2.0 screening by rescoring AF3-predicted complexes (Shen et al. 2025 Table 2, AF3 block) | 10 evaluations · 100 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DEKOIS 2.0 screening by rescoring Protenix-predicted complexes (Shen et al. 2025 Table 2, Protenix block) | 13 evaluations · 130 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DEKOIS 2.0 screening with co-folding confidence scores against docking tools (Shen et al. 2025 Table 1) | 24 evaluations · 240 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DELFI 2019 internally cross-validated cancer detection protocol | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Depletion of high-scoring splice-proximal SNVs in gnomAD, TOPMed and UK Biobank, high-pLI genes (SpliceAI2 paper, Spearman) | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Detection of 16 known pathogenic splicing events in clinical muscle RNA-seq (Segarra-Casas et al. Table 2) | 5 evaluations · 80 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Detection of RT-PCR-positive viruses per sample, with assigned read counts (de Vries et al. 2021 Supplementary Table 2) | 13 evaluations · 221 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Diagnostic sensitivity, day 0 or 1 (Wolf et al. 2026 Table 2) | 1 evaluation · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DNA language model inference throughput and maximum batch size on one A100 80 GB by sequence length (Aspidova et al. 2026 Table 2) | 9 evaluations · 92 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DNALONGBENCH Contact map prediction (Table 4) | 5 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DNALONGBENCH Enhancer-target gene prediction (Table 3) | 5 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DNALONGBENCH Expression quantitative trait loci prediction (Table 7) | 5 evaluations · 50 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DNALONGBENCH Regulatory sequence activity prediction (Table 5) | 5 evaluations · 15 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DNALONGBENCH Transcription initiation signal prediction (Table 6) | 5 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DNase prediction on held-out peaks (AlphaGenome paper) | 2 evaluations · 6 rows | 3 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DNase track prediction at 128 bp (AlphaGenome paper) | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DNase track prediction at 32 bp (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| DNM1 minigene screen, active versus inactive variants, average precision (AlphaGenome Atlas) | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Docking score of designed ligand pockets | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| DREAM synthetic set 1 somatic SNVs, WGS (Wang et al. 2020 Table S1) | 15 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DREAM synthetic set 2 somatic SNVs, WGS (Wang et al. 2020 Table S1) | 15 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DREAM synthetic set 3 somatic indels, WGS (Wang et al. 2020 Table S2) | 12 evaluations · 48 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DREAM synthetic set 3 somatic SNVs, WGS (Wang et al. 2020 Table S1) | 15 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DREAM synthetic set 4 somatic indels, WGS (Wang et al. 2020 Table S2) | 12 evaluations · 48 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| DREAM synthetic set 4 somatic SNVs, WGS (Wang et al. 2020 Table S1) | 15 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Driver fusions, conventional RNA-seq of haematologic cell lines, validated truth (Tamura et al. 2026 Supplementary Table 5) | 12 evaluations · 72 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Driver fusions, targeted RNA-seq of haematologic cell lines, validated truth (Tamura et al. 2026 Supplementary Table 5) | 12 evaluations · 72 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| E. coli sigma70 independent promoter test (E. coli sigma70 promoter prediction) | 15 evaluations · 60 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| EC classification (DGEB) (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| EC, DeepFRI split (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| EC, SaProt split (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| EditJumps frame with the reference alignment expanded to 800 homologs: spectrum MMD | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| EditJumps section 4.2 frame, 200 references: cov. agr. | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| EditJumps section 4.2 frame, 200 references: edits | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| EditJumps section 4.2 frame, 200 references: JS pos. | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| EditJumps section 4.2 frame, 200 references: KL pool. | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| EditJumps section 4.2 frame, 200 references: KL pos. | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| EditJumps section 4.2 frame, 200 references: MIP agr. | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| EditJumps section 4.2 frame, 200 references: MMD | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| EditJumps section 4.2 frame, 200 references: pairw. Lev. | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| EditJumps section 4.2 frame, 200 references: prof. LL | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| EditJumps section 4.2 frame, 200 references: ΔH | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Embedding throughput on one NVIDIA H20 (HyPLM report) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ENCODE4 within-donor organ pairs, Pearson r of predicted against measured isoform change | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Enformer CAGE gene-expression comparison | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Enformer CAGE gene-expression comparison Across genes CAGE Pearson: Mean across-experiment Pearson correlation of human test-gene CAGE expression | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| EnFusion undiluted Seraseq duplicate benchmark | 4 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ENIGMA specification pilot resolution | 1 evaluation · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Enzyme-pair functional identity: original held-out test (Enzyme functional identity prediction) | 5 evaluations · 40 rows | 8 source-scoped figures | Checked result tables available.Scope and remaining work
|
| eQTL effect direction (AlphaGenome paper) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| eQTL effect-size ranking (AlphaGenome paper) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| ESMFold2 Runs N’ Poses reported comparison msa: Runs N’ Poses ligand pass rate (MSA) | 7 evaluations · 7 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ESMFold2 Runs N’ Poses reported comparison single-sequence: Runs N’ Poses ligand pass rate (single sequence) | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| European-ancestry LCL caQTL classification (AlphaGenome paper) | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| European-ancestry LCL caQTL effect-size prediction (AlphaGenome paper) | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| EVEE ClinVar indel pathogenicity AUROC (Pearce et al. 2026 Figure 1d) | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| EVEE deconfounded ClinVar SNV pathogenicity AUROC (Pearce et al. 2026 Figure 1c) | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| EVEE Evo 2 embedding extraction compute (Pearce et al. 2026) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Evo 2 7B BRCA1 variant scoring throughput on one GPU (evo2-cloud-operations W1) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| EvoFlows published values, two families: diversity | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| EvoFlows published values, two families: edits/seq | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| EvoFlows published values, two families: KL x10^3 | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| EvoFlows published values, two families: MMD | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Excess panel-matched rare variants in Genomics England rare-disease probands at panel-match odds ratio 2 (SpliceAI2 paper) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Exomiser rank-budget recovery in ACG trios | 1 evaluation · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Exon-level CNV detection in clinical exomes against CMA truth, after removing tool-specific problematic regions (Hwang et al. Table 4, post-filter) | 4 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Exon-level CNV detection in clinical exomes against CMA truth, default calls (Hwang et al. Table 4, pre-filter) | 4 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| False positives in seven pathogen-free libraries (Tisza et al. 2026 Table S6) | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FAS exon 6 saturation MPSA: transcriptome-normalised sensitivity at a 10% background call rate (Smith and Kitzman Table S2) | 8 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FASTQ-to-VCF runtime, core-hours and Azure cost of three Sentieon DNAscope pipelines on one 120-vCPU instance (Hu et al. 2026 Table 2) | 3 evaluations · 21 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng A.Thaliana 4mC sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Acceptor sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng C.Elegans 4mC sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Coding sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng D.Melanogaster 4mC sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng DNase I Hypersensitive sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Donor sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng E.Coli 4mC sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Enhancer Cohn sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Enhancer Ensembl sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Enhancer sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng eQTL discrimination | 24 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng G.Pickeringii 4mC sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng G.Subterraneus 4mC sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng GTEx whole-blood expression prediction, 768 genes, long input | 3 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng GTEx whole-blood expression prediction, all genes, 6 kb input | 5 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Human 5mC sequence classification | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Human 6 mA sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Human TFBS 1 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Human TFBS 2 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Human TFBS 3 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Human TFBS 4 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Human TFBS 5 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Human vs worm sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng ipaQTL discrimination | 24 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Mouse TFBS 1 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Mouse TFBS 2 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Mouse TFBS 3 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Mouse TFBS 4 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Mouse TFBS 5 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Open chromatin region sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng paQTL discrimination | 24 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng pathogenic-versus-common SNP classification | 22 evaluations · 55 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Promoter All 300 bps sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Promoter All 70 bps sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Promoter Arabidopsis NonTATA sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Promoter Arabidopsis TATA sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Promoter B.Amyloliquefaciens sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Promoter GM12878 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Promoter Hela-S3 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Promoter HUVEC sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Promoter NHEK sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Promoter NonTATA 251 bps sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Promoter NonTATA 300 bps sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Promoter NonTATA 70 bps sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Promoter R.Capsulatus sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Promoter TATA 300 bps sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Promoter TATA 70 bps sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng sQTL discrimination | 24 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng TAD recognition from NT-v2 attention | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Feng Yeast H3 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Yeast H3K14ac sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Yeast H3K36me3 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Yeast H3K4me1 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Yeast H3K4me2 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Yeast H3K4me3 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Yeast H3K79me3 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Yeast H3K9ac sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Yeast H4 sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Feng Yeast H4ac sequence classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FEP+ benchmark four-target subset, affinity ranking and cost | 10 evaluations · 100 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FEP+ benchmark OpenFE subset, affinity ranking | 6 evaluations · 54 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fine-tuning and evaluation wall time, 5 epochs on the Enformer eQTL dataset (Hegde et al. 2025 Table A1) | 1 evaluation · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fine-tuning wall time to convergence on the Enformer eQTL dataset (Hegde et al. 2025 Methods) | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fingerprint prediction from MS/MS, MassSpecGym random split, assumption (1) (Khoo 2026) | 5 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fingerprint prediction from MS/MS, MassSpecGym random split, assumption (2) (Khoo 2026) | 5 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fingerprint prediction from MS/MS, MassSpecGym random split, assumption (3) (Khoo 2026) | 6 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fingerprint prediction from MS/MS, MassSpecGym scaffold split, assumption (1) (Khoo 2026) | 5 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fingerprint prediction from MS/MS, MassSpecGym scaffold split, assumption (2) (Khoo 2026) | 5 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fingerprint prediction from MS/MS, MassSpecGym scaffold split, assumption (3) (Khoo 2026) | 6 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fingerprint prediction from MS/MS, NPLIB1 random split, assumption (1) (Khoo 2026) | 5 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fingerprint prediction from MS/MS, NPLIB1 random split, assumption (2) (Khoo 2026) | 5 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fingerprint prediction from MS/MS, NPLIB1 random split, assumption (3) (Khoo 2026) | 6 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fingerprint prediction from MS/MS, NPLIB1 scaffold split, assumption (1) (Khoo 2026) | 5 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fingerprint prediction from MS/MS, NPLIB1 scaffold split, assumption (2) (Khoo 2026) | 5 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fingerprint prediction from MS/MS, NPLIB1 scaffold split, assumption (3) (Khoo 2026) | 6 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fireprot homologue-free split ddG prediction (Dieckhaus et al. 2024 Table 2) | 12 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Flagging new reanalysis candidates from Exomiser score changes across database releases (Vestito et al. 2024 Supplementary Table 1) | 81 evaluations · 648 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FlexMS molecule-to-spectrum prediction on MassSpecGym, embedder-predictor grid (Table 2) | 33 evaluations · 66 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FLIP2 Amylase by-mutation; held-out test set · Amylase | 9 evaluations · 18 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP2 Amylase close-to-far; held-out test set · Amylase | 9 evaluations · 17 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP2 Amylase far-to-close; held-out test set · Amylase | 9 evaluations · 18 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP2 Amylase one-to-many; held-out test set · Amylase | 9 evaluations · 18 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP2 hydro low-to-high; held-out test set · hydro | 9 evaluations · 18 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP2 hydro three-to-many; held-out test set · hydro | 9 evaluations · 18 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP2 hydro to-P01053; held-out test set · hydro | 9 evaluations · 17 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP2 hydro to-P06241; held-out test set · hydro | 9 evaluations · 18 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP2 hydro to-P0A9X9; held-out test set · hydro | 9 evaluations · 18 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP2 IRED two-to-many; held-out test set · IRED | 9 evaluations · 18 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP2 NucB two-to-many; held-out test set · NucB | 9 evaluations · 18 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP2 PDZ3 single-to-double; held-out test set · PDZ3 | 9 evaluations · 17 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP2 Rhomax by_wild_type | 5 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP2 rhomax by-wild-type; held-out test set · rhomax | 9 evaluations · 17 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP2 TrpB by-position; held-out test set · TrpB | 9 evaluations · 18 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP2 TrpB one-to-many; held-out test set · TrpB | 9 evaluations · 17 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| FLIP2 TrpB two-to-many; held-out test set · TrpB | 9 evaluations · 18 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Fluorescence (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FoldBench antibody-antigen published full-set assessment | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FoldBench dna-monomer published full-set assessment | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FoldBench protein-dna published full-set assessment | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FoldBench protein-ligand published full-set assessment | 5 evaluations · 15 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FoldBench protein-monomer published full-set assessment | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FoldBench protein-peptide published full-set assessment | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FoldBench protein-protein published full-set assessment | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FoldBench protein-rna published full-set assessment | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FoldBench rna-monomer published full-set assessment | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fragmentia-AI paper: ULP-WGS cancer vs non-cancer AUC on a held-out validation set, six feature sets x three classifiers | 19 evaluations · 19 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fragmentia-AI WGS paper: External DELFI cohort (FinaleDB) | 1 evaluation · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fragmentia-AI WGS paper: Independent test cohort by ichorCNA tumour fraction | 1 evaluation · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fragmentia-AI WGS paper: Internal validation cohort by ichorCNA tumour fraction | 3 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Fragmentia-AI WGS paper: Training cohort (resubstitution) | 2 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FramePool study MRL: Human 25-100nt | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FramePool study MRL: Human 50nt | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FramePool study MRL: Random 25-100nt | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FramePool study MRL: Random 50nt | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| FRASER Kremer cohort known pathogenic-event subsampling | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Frozen project benchmark Atomic Motif Enzyme, fixed ligand: distinct passers per GPU-hour | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Frozen project benchmark DNA binding, fixed DNA: distinct passers per GPU-hour | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Frozen project benchmark DNA binding, unfixed DNA: distinct passers per GPU-hour | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Frozen project benchmark protein binding, all-atom conditioning: distinct passers per GPU-hour | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Frozen project benchmark protein binding, backbone conditioning: distinct passers per GPU-hour | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Frozen project benchmark small-molecule binding, unfixed ligand: distinct passers per GPU-hour | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Gain in scTM at fixed diversity from reinforcement learning (HyInv report) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Gain in scTM at fixed diversity over the unmodified sampler (HyInv report) | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| gamma-delta T against tissue-resident CD8 T split, ARI (HyCell report) | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GB1 low-vs-high (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GB1 three-vs-rest (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GB1 two-vs-rest (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GEARS Norman2019 CPA-control comparison | 4 evaluations · 8 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GEARS Norman2019 CPA-control comparison MSE: Norman2019 perturbation-response MSE | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GEARS Norman2019 CPA-control comparison Pearson DE: Norman2019 perturbation-response Pearson DE | 4 evaluations · 4 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GenBench Bulk RNA expression | 5 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Coding vs Intergenomic | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Drosophila enhancer activity (dev) | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Drosophila enhancer activity (hk) | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Drosophila enhancer activity (Mean) | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Genomic structure prediction (H1-ESC) | 6 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Genomic structure prediction (HFF) | 6 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Core Promoter Detection | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Core Promoter Detection, dataset all | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Core Promoter Detection, dataset notata | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Core Promoter Detection, dataset tata | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Enhancers Cohn | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Enhancers Ensembl | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Ensembl Regulatory | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Nontata Promoters | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human OCR Ensembl | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Promoter Detection | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Promoter Detection, dataset all | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Promoter Detection, dataset notata | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Promoter Detection, dataset tata | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Splice Site Detection | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Transcription Factor Prediction | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Transcription Factor Prediction, dataset 0 | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Transcription Factor Prediction, dataset 1 | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Transcription Factor Prediction, dataset 2 | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Transcription Factor Prediction, dataset 3 | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human Transcription Factor Prediction, dataset 4 | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Human vs Worm | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Long-range Promoters Prediction | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Long-range Species Classification | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Long-range splice site prediction (Mean) | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Long-range splice site prediction (Splice acceptor) | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Long-range splice site prediction (Splice donar) | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Mouse Enhancers | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Mouse Transcription Factor Prediction | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Mouse Transcription Factor Prediction, dataset 0 | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Mouse Transcription Factor Prediction, dataset 1 | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Mouse Transcription Factor Prediction, dataset 2 | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Mouse Transcription Factor Prediction, dataset 3 | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Mouse Transcription Factor Prediction, dataset 4 | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Virus Covid Variant Classification | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Yeast Epigenetic Marks Prediction | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Yeast Epigenetic Marks Prediction, dataset H3 | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Yeast Epigenetic Marks Prediction, dataset H3K14ac | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Yeast Epigenetic Marks Prediction, dataset H3K36me3 | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Yeast Epigenetic Marks Prediction, dataset H3K4me1 | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Yeast Epigenetic Marks Prediction, dataset H3K4me2 | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Yeast Epigenetic Marks Prediction, dataset H3K4me3 | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Yeast Epigenetic Marks Prediction, dataset H3K79me3 | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Yeast Epigenetic Marks Prediction, dataset H3K9ac | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Yeast Epigenetic Marks Prediction, dataset H4 | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenBench Yeast Epigenetic Marks Prediction, dataset H4ac | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Gene region classification from averaged GPN embeddings, leave-one-chromosome-out | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Gene-level logistic regression under 5-fold GroupKFold by perturbation (Kendiukhov 2026) | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Gene-MTEB genomic embedding benchmark HMPD-disease: HMPD-disease genomic embedding evaluation | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Gene-MTEB genomic embedding benchmark HMPD-sex: HMPD-sex genomic embedding evaluation | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Gene-MTEB genomic embedding benchmark HMPD-single: HMPD-single genomic embedding evaluation | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Gene-MTEB genomic embedding benchmark HMPD-source: HMPD-source genomic embedding evaluation | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Gene-MTEB genomic embedding benchmark HMPR-p2p: HMPR-p2p genomic embedding evaluation | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Gene-MTEB genomic embedding benchmark HMPR-s2s-align: HMPR-s2s-align genomic embedding evaluation | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Gene-MTEB genomic embedding benchmark HMPR-s2s-small: HMPR-s2s-small genomic embedding evaluation | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Gene-MTEB genomic embedding benchmark HMPR-s2s-tiny: HMPR-s2s-tiny genomic embedding evaluation | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Gene-MTEB genomic embedding benchmark Human-Virus-1: Human-Virus-1 genomic embedding evaluation | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Gene-MTEB genomic embedding benchmark Human-Virus-2: Human-Virus-2 genomic embedding evaluation | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Gene-MTEB genomic embedding benchmark Human-Virus-3: Human-Virus-3 genomic embedding evaluation | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Gene-MTEB genomic embedding benchmark Human-Virus-4: Human-Virus-4 genomic embedding evaluation | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Gene-MTEB genomic embedding benchmark HVR-p2p: HVR-p2p genomic embedding evaluation | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Gene-MTEB genomic embedding benchmark HVR-s2s-align: HVR-s2s-align genomic embedding evaluation | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Gene-MTEB genomic embedding benchmark HVR-s2s-small: HVR-s2s-small genomic embedding evaluation | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Gene-MTEB genomic embedding benchmark HVR-s2s-tiny: HVR-s2s-tiny genomic embedding evaluation | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Gene-program consistency across donors, classical to nonclassical monocytes (HyCell report) | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Gene-program consistency across donors, naive B to plasma cells (HyCell report) | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Gene-program consistency across donors, naive to effector CD4 T cells (HyCell report) | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GENEB leaderboard, 1-shot, MCC aggregates | 41 evaluations · 615 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GENEB leaderboard, 10-shot, MCC aggregates | 41 evaluations · 615 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GENEB leaderboard, full training data, MCC aggregates | 41 evaluations · 615 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GeneRNIB 300BCG GRN inference, 50,000-link budget, official all_metrics scoring (PerturbPFN Table 3) | 6 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Genie 3 short monomer generation designability: Unconditional short monomer Designability | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genie 3 short monomer generation diversity-tm-05: Unconditional short monomer Diversity, TM < 0.5 | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genie 3 short monomer generation diversity-tm-06: Unconditional short monomer Diversity, TM < 0.6 | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genie 3 short monomer generation novelty-afdb: Unconditional short monomer Novelty, AFDB | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genie 3 short monomer generation novelty-pdb: Unconditional short monomer Novelty, PDB | 13 evaluations · 13 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Genome-wide prophage detection (Genome-wide prophage detection) | 17 evaluations · 102 rows | 6 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GenomeOcean embedding extraction throughput, peak VRAM and binning fidelity, BF16 versus FP8 weights (Yu et al. 2026 Table 3) | 6 evaluations · 21 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GenomeOcean-4B autoregressive generation throughput, power, energy efficiency and perplexity, BF16 versus FP8 (Yu et al. 2026 Table 4) | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Genus-level read classification of ONT bacterial isolates, main database (Peres da Silva et al. 2024) | 3 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Germline FASTQ-to-VCF runtime by read depth, Parabricks v4.3.0 on V100 and A100 GPUs versus the CPU GATK equivalent (Marangoni et al. 2026 Table S1) | 4 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API Bend Variant Effects Disease, zs-ar-llr | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API Bend Variant Effects Disease, zs-embedding | 5 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API Bend Variant Effects Disease, zs-mlm-llr | 4 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API Bend Variant Effects Expression, zs-ar-llr | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API Bend Variant Effects Expression, zs-embedding | 5 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API Bend Variant Effects Expression, zs-mlm-llr | 4 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API BRCA1, zs-ar-llr | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API BRCA1, zs-embedding | 5 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API BRCA1, zs-mlm-llr | 4 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API ClinVar Indel Pathogenicity, zs-ar-llr | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API ClinVar Indel Pathogenicity, zs-embedding | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API GUE Promoter All, supervised | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API GUE Splice Site, supervised | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API GUE Transcription Factor, supervised | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API LOL-EVE, zs-ar-llr | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API LOL-EVE, zs-embedding | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API LRB Variant Effect Causal eQTL, supervised | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API LRB Variant Effect OMIM, zs-ar-llr | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API LRB Variant Effect OMIM, zs-embedding | 5 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API LRB Variant Effect OMIM, zs-mlm-llr | 4 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API Songlab ClinVar, zs-ar-llr | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API Songlab ClinVar, zs-embedding | 5 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API Songlab ClinVar, zs-mlm-llr | 4 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API TraitGym Complex, zs-ar-llr | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API TraitGym Complex, zs-embedding | 5 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API TraitGym Complex, zs-mlm-llr | 4 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API TraitGym Mendelian, zs-ar-llr | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API TraitGym Mendelian, zs-embedding | 5 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API TraitGym Mendelian, zs-mlm-llr | 4 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API Var Bench Coding Pathogenicity, supervised | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API Var Bench Common Vs Rare, supervised | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API Var Bench Expression, supervised | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API Var Bench meQTL, supervised | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API Var Bench Non Coding Pathogenicity, supervised | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API Var Bench sQTL, supervised | 4 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API VEP-eval, zs-embedding | 4 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GFMBench-API VEP-eval, zs-mlm-llr | 4 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GlycanML class Accuracy: GlycanGT study: class Accuracy | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML class Macro-F1: GlycanGT study: class Macro-F1 | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML domain Accuracy: GlycanGT study: domain Accuracy | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML domain Macro-F1: GlycanGT study: domain Macro-F1 | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML family Accuracy: GlycanGT study: family Accuracy | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML family Macro-F1: GlycanGT study: family Macro-F1 | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML genus Accuracy: GlycanGT study: genus Accuracy | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML genus Macro-F1: GlycanGT study: genus Macro-F1 | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML glycosylation Accuracy: GlycanGT study: glycosylation Accuracy | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML glycosylation Macro-F1: GlycanGT study: glycosylation Macro-F1 | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML immunogenicity Accuracy: GlycanGT study: immunogenicity Accuracy | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML immunogenicity AUPRC: GlycanGT study: immunogenicity AUPRC | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML immunogenicity Macro-F1: GlycanGT study: immunogenicity Macro-F1 | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML kingdom Accuracy: GlycanGT study: kingdom Accuracy | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML kingdom Macro-F1: GlycanGT study: kingdom Macro-F1 | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML order Accuracy: GlycanGT study: order Accuracy | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML order Macro-F1: GlycanGT study: order Macro-F1 | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML phylum Accuracy: GlycanGT study: phylum Accuracy | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML phylum Macro-F1: GlycanGT study: phylum Macro-F1 | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML species Accuracy: GlycanGT study: species Accuracy | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlycanML species Macro-F1: GlycanGT study: species Macro-F1 | 5 evaluations · 5 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| GlyConnect glycosylation · Glycos (GlycanML glycosylation type prediction) | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| gnomAD rare versus common enrichment in the deleterious tail, odds ratio (GPN-Star Fig. 4b) | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| gnomAD rare vs common enrichment in the deleterious tail, odds ratio (GPN-MSA Supplementary Table 4) | 17 evaluations · 34 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GO-BP (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GO-CC (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GO-MF (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GPCRrecent screening (16 GPCR targets) (Shen et al. 2025 Table 3) | 14 evaluations · 140 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GPCRrecent screening (the six targets whose first structures postdate the Boltz-2 training cutoff) (Shen et al. 2025 Table 3) | 2 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GREGoR solved cases, recall of causal variants in the top 50 per patient (AlphaGenome Atlas) | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GTEx tissue-specific splicing prediction, Splice acceptors and donors (You et al. 2026 Supplementary Table 5) | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GTEx tissue-specific splicing prediction, Splice-15class (You et al. 2026 Supplementary Table 5) | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GTEx tissue-specific splicing prediction, Splice-53class (You et al. 2026 Supplementary Table 5) | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GTEx v8 fine-mapped sQTL effect size prediction (SpliceAI2 paper, Spearman) | 4 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GTEx v8 fine-mapped sQTL SNVs against non-prioritised SNVs near junction ends (SpliceAI2 paper, auROC) | 4 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GUANinE v1.1 cadd-snv, Spearman rho x100 (Table 3) | 23 evaluations · 23 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GUANinE v1.1 ccre-propensity, Spearman rho x100 (Table 2) | 32 evaluations · 32 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GUANinE v1.1 clinvar-snv, Spearman rho x100 (Table 4) | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GUANinE v1.1 cons100, Spearman rho x100 (Table 2) | 32 evaluations · 32 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GUANinE v1.1 cons30, Spearman rho x100 (Table 2) | 32 evaluations · 32 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GUANinE v1.1 dnase-propensity, Spearman rho x100 (Table 2) | 32 evaluations · 32 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GUANinE v1.1 gpra-c, Spearman rho x100 (Table 2) | 31 evaluations · 31 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GUANinE v1.1 gpra-d, Spearman rho x100 (Table 2) | 31 evaluations · 31 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| GWAS hit enrichment in the lowest 1% of scores, AraGWAS permutation threshold | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HaplotypeCaller execution on CPU and GPU cloud and DGX machines (O'Connell et al. 2023 Table 1) | 11 evaluations · 42 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HECTOR vs. ENIGMA Evidence Repository (eRepo) agreement | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Held-out CRISPR enhancer-gene benchmark, weighted metrics, five cell types (Gschwind et al. 2026 Supplementary Table 3) | 6 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Held-out human-versus-virus protein classification (human-versus-viral protein classification) | 8 evaluations · 32 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Held-out trials, immunotherapy response AUROC, equal mean over six trials | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Held-out trials, OS hazard ratio of higher- against lower-risk half, geometric mean over six trials | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Held-out trials, OS Uno C-index weighted by trial size, TCGA plus non-trial cohorts plus other trials training pool | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Held-out trials, PFS hazard ratio of higher- against lower-risk half, geometric mean over three trials | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Helzer et al. 2025 Razavi et al. 2019 GRAIL cohort, FoundationOne Liquid CDx gene subset: multinomial phenotype AUROC | 13 evaluations · 65 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Helzer et al. 2025 Razavi et al. 2019 GRAIL cohort, full panel: multinomial phenotype AUROC | 13 evaluations · 65 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Helzer et al. 2025 Razavi et al. 2019 GRAIL cohort, Guardant360 CDx gene subset: multinomial phenotype AUROC | 13 evaluations · 65 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Helzer et al. 2025 Razavi et al. 2019 GRAIL cohort, Tempus xF gene subset: multinomial phenotype AUROC | 13 evaluations · 65 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Helzer et al. 2025 UW cohort, FoundationOne Liquid CDx gene subset: multinomial phenotype AUROC | 13 evaluations · 130 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Helzer et al. 2025 UW cohort, full panel: multinomial phenotype AUROC | 14 evaluations · 140 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Helzer et al. 2025 UW cohort, Guardant360 CDx gene subset: multinomial phenotype AUROC | 13 evaluations · 130 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Helzer et al. 2025 UW cohort, Tempus xF gene subset: multinomial phenotype AUROC | 13 evaluations · 130 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HG002 DRAGEN full single-genome runtime on Phase4 | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HG002 exon-overlap CNV benchmark by event type and length (De La Vega et al. Table S3) | 8 evaluations · 176 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HG002 GIAB v0.6 CNV deletion [10,000-20,0000) bp (DRAGEN Table S4) | 3 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HG002 GIAB v0.6 CNV deletion [20,000-50,000) bp (DRAGEN Table S4) | 3 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HG002 GIAB v0.6 CNV deletion [5,000-10,000) bp (DRAGEN Table S4) | 3 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HG002 GIAB v0.6 CNV deletion >50,000 bp (DRAGEN Table S4) | 3 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HG002 GIAB v0.6 CNV deletion 1–5kb F-score | 3 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HG002 short-read deletion calling by length bin, witty.er (Nardone et al. Table S1) | 10 evaluations · 240 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HG003 ONT WGS small-variant accuracy against GIAB v4.2.1, Clair3 versus DeepVariant (Zheng et al. 2026 Supplementary Table 3) | 3 evaluations · 135 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HG003 ONT WGS variant-calling runtime, memory and I/O, Clair3 versus DeepVariant in GPU mode (Zheng et al. 2026 Supplementary Table 2) | 2 evaluations · 40 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HG003 PacBio Revio WGS small-variant accuracy against GIAB v4.2.1, Clair3 versus DeepVariant (Zheng et al. 2026 Supplementary Table 3) | 3 evaluations · 135 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HG003 PacBio Revio WGS variant-calling runtime, memory and I/O, Clair3 versus DeepVariant in GPU mode (Zheng et al. 2026 Supplementary Table 2) | 2 evaluations · 40 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HG008 all-benchmark region (sensitivity analysis), SNVs and indels combined, Mutect2, Strelka2, DeepSomatic and ensembles (Hasan 2026 Table 4) | 6 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HG008 primary region (nogermlineinterference), indels, Mutect2, Strelka2, DeepSomatic and ensembles (Hasan 2026 Table 2, Class 'INDEL') | 6 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HG008 primary region (nogermlineinterference), SNVs and indels combined, Mutect2, Strelka2, DeepSomatic and ensembles (Hasan 2026 Table 1) | 6 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HG008 primary region (nogermlineinterference), SNVs, Mutect2, Strelka2, DeepSomatic and ensembles (Hasan 2026 Table 2, Class 'SNV') | 6 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HGMD pathogenic vs gnomAD common regulatory variants, AUPRC (GPN-Star Supplementary Table 3) | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HGMD/gnomAD missense pathogenicity, ESM1b head to head with one other method on the variants both score (Brandes et al. 2023 Fig. 2g,h, Supplementary Table 2) | 90 evaluations · 180 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HGMD/gnomAD missense pathogenicity, ESM1b versus EVE on variants scored by both (Brandes et al. 2023 Fig. 2b, Results text) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| HGMD/gnomAD missense pathogenicity, variants scored by all 19 eligible methods (Brandes et al. 2023 Fig. 2e-f, Supplementary Table 2) | 19 evaluations · 38 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HiFi ATCC MSA-1003 mock community (PacBio Sequel II HiFi): species detection at 0.001% of total reads (Portik et al. 2022 Table 4) | 14 evaluations · 112 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HiFi ZymoBIOMICS D6331 gut microbiome standard (PacBio Sequel II HiFi): species detection at 0.001% of total reads (Portik et al. 2022 Table 4) | 14 evaluations · 112 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| histone ChIP-seq track prediction at 128 bp (AlphaGenome paper) | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| histone ChIP-seq track prediction at 32 bp (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) | 10 evaluations · 220 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Hou et al. 2024 independent validation, Mathios et al. independent lung cohort (Table S3) | 10 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Hou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3) | 10 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) | 10 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Hou et al. 2024 Jiang cohort cross-validation, liver cancer (Table S2) | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Hou et al. 2024 pan-cancer vs healthy, Cristiano cohort, 10 x 10-fold cross-validation (Table 1 AUC) | 25 evaluations · 25 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| How well ipTM tracks DockQ on cognate nanobody-antigen complexes | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Hu 2026 BRCA2 functional-integration classification yield | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Huh7 recovery of 34 previously reported fusions by library type, union of callers (Dorney et al. 2026) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Human RNA 2OMe sites, five-fold cross-validation (human RNA 2-prime-O-methylation site prediction) | 7 evaluations · 49 rows | 7 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Human RNA 2OMe sites, independent test set (human RNA 2-prime-O-methylation site prediction) | 5 evaluations · 35 rows | 7 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Human splice-junction classification and count prediction (AlphaGenome paper) | 2 evaluations · 4 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Human splice-site classification: annotation-derived (AlphaGenome paper) | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Human splice-site classification: RNA-derived (AlphaGenome paper) | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Human splice-site usage (AlphaGenome paper) | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| HumanPPI (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HuRI PPI link prediction, Accuracy (Table 6) | 77 evaluations · 77 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HuRI PPI link prediction, Hits@100 (Table 5) | 77 evaluations · 77 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Hydrolase to P06241 (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| HyInv above the ProteinMPNN temperature curve at HyInv's diversity (HyInv report) | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Identify all pathogens and the causal pathogen in one clinical blood metagenome (CAMI II clinical pathogen challenge) | 8 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Illumina ATCC MSA-1003 mock community (HiSeq 2500): species detection at 0.001% of total reads (Portik et al. 2022 Table 4) | 7 evaluations · 56 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Illumina COLO829 tumour-only, 50x, somatic indels (Chen et al. 2025 Supplementary Table 7b) | 6 evaluations · 42 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Illumina COLO829 tumour-only, 50x, somatic SNVs (Chen et al. 2025 Supplementary Table 7b) | 6 evaluations · 42 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Illumina ZymoBIOMICS D6300 standard (NovaSeq 6000), subsampled: species detection at 0.001% of total reads (Portik et al. 2022 Table 4) | 7 evaluations · 56 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| In vitro activity of Evo-generated mobile-element designs (Nguyen et al. 2024) | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Independent replication of 1-gene perturbation design: cumulative hits after 5 rounds of 128 genes | 55 evaluations · 55 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| INSR isoform split in TCGA stomach tumours, mean absolute error | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| INSR isoform split in TCGA stomach tumours, Pearson r | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Isoform variation in eight held-out TCGA cancer types, median Pearson r over gene and cancer-type pairs | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Jores 2021 promoter strength: maize-protoplasts | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Jores 2021 promoter strength: tobacco-leaves | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| K562 ONT long-read RNA-seq, recovery of 6 known fusions and count of other calls (Dorney et al. 2026) | 6 evaluations · 152 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Karius 2019 plasma microbial cfDNA positive agreement with initial blood culture protocol | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Kedzierska et al. 2025 cell embedding scoring after UMAP projection | 56 evaluations · 360 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Kedzierska et al. 2025 cell embedding scoring, full embedding dimensions | 56 evaluations · 416 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Kedzierska et al. 2025 Geneformer pretraining-objective reconstruction | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| KIBA drug-target affinity, DeepDTA holdout fold | 16 evaluations · 32 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Lancet paper virtual-tumor SNV/indel benchmark | 2 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Latency of a design request on one NVIDIA H20 (HyInv report) | 13 evaluations · 23 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| LectinOracle interaction · Interaction (GlycanML protein-glycan interaction prediction) | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Ligand-pocket computational pass rate under TorchScore confidence | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Lin et al. 2025 CIViC evidence-level assignment | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Lin et al. 2025 FoundationOne variants: clinically relevant vs VUS | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Lin et al. 2025 OncoKB level-of-evidence assignment | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Lipase EstA dataset stability ranking, Spearman correlation (Chu et al. 2024 Table 1) | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| LiPP Table 2: lipid pose all-atom RMSD below 2 Angstrom, Full LiPP set | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| LiPP Table 2: lipid pose all-atom RMSD below 2 Angstrom, LiPP test set | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| LiPP Table 2: lipid pose all-atom RMSD below 2 Angstrom, PoseBusters v1 | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| LiPP Table 2: lipid pose all-atom RMSD below 2 Angstrom, PoseBusters v2 | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| LiPP Table 3: RMSD below 2 Angstrom and PoseBusters valid, Full LiPP set | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| LiPP Table 3: RMSD below 2 Angstrom and PoseBusters valid, LiPP test set | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| LiPP Table 3: RMSD below 2 Angstrom and PoseBusters valid, PoseBusters v2 | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| LIT-PCBA five-target screening (Shen et al. 2025 Table 4) | 7 evaluations · 84 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Livesey and Marsh 2025 clinical benchmark: pairwise AUROC win rate, ClinVar pathogenic versus gnomAD missense | 85 evaluations · 85 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets | 97 evaluations · 194 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, direct assays only | 97 evaluations · 97 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, indirect assays only | 97 evaluations · 97 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions only | 97 evaluations · 97 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions with gaps filled | 97 evaluations · 97 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Local likelihood ratio at developer-recommended thresholds (Pejaver et al. 2022 Table 3) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Localization, 10-class (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Localization, binary (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| LoFreq execution on CPU and GPU cloud and DGX machines (O'Connell et al. 2023 Table 1) | 11 evaluations · 42 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Low-mutation-burden tumours (AML, MBL, CLL), tumour-only SNVs, AUPRC (Krishnamachari et al. 2026 Supplementary Table 4) | 9 evaluations · 27 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 Monomeric RNA easy set, GDT-TS success rate | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 Monomeric RNA easy set, INF success rate | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 Monomeric RNA easy set, lDDT success rate | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 Monomeric RNA easy set, mean GDT-TS | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 Monomeric RNA easy set, mean INF | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 Monomeric RNA easy set, mean lDDT | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 Monomeric RNA easy set, mean TM-score | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 Monomeric RNA easy set, TM-score success rate | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 Monomeric RNA hard set, GDT-TS success rate | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 Monomeric RNA hard set, INF success rate | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 Monomeric RNA hard set, lDDT success rate | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 Monomeric RNA hard set, mean GDT-TS | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 Monomeric RNA hard set, mean INF | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 Monomeric RNA hard set, mean lDDT | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 Monomeric RNA hard set, mean TM-score | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 Monomeric RNA hard set, TM-score success rate | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 RNA complex easy set, mean DockQ | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 RNA complex easy set, mean F1 | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 RNA complex easy set, mean fnat | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 RNA complex easy set, mean iRMSD | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 RNA complex easy set, mean LRMSD | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 RNA complex easy set, mean TM-score | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 RNA complex hard set, mean DockQ | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 RNA complex hard set, mean F1 | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 RNA complex hard set, mean fnat | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 RNA complex hard set, mean iRMSD | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 RNA complex hard set, mean LRMSD | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 RNA complex hard set, mean TM-score | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 RNA-protein interfaces, mean per-interface DockQ | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ludaic and Elofsson 2026 RNA-RNA interfaces, mean per-interface DockQ | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| M. tuberculosis read classification, real Illumina (Hall and Coin 2024 Table 8) | 6 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| M. tuberculosis read classification, real Nanopore (Hall and Coin 2024 Table 6) | 6 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| M. tuberculosis read classification, simulated Illumina (Hall and Coin 2024 Table 7) | 6 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| M. tuberculosis read classification, simulated Nanopore (Hall and Coin 2024 Table 5) | 6 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Manual versus Talos reanalysis of 219 unresolved genomes after a mean 660 days (Kaschta et al. 2026) | 2 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Masked-residue perplexity, held-out UniRef panel (HyPLM report) | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Masked-residue perplexity, recent PDB chains (HyPLM report) | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MassSpecGym · formula (MassSpecGym De novo molecule generation) | 3 evaluations · 18 rows | 6 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MassSpecGym · formula (MassSpecGym Molecule retrieval) | 5 evaluations · 20 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MassSpecGym · formula (MassSpecGym Spectrum simulation) | 4 evaluations · 20 rows | 3 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MassSpecGym · main (MassSpecGym De novo molecule generation) | 3 evaluations · 18 rows | 6 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MassSpecGym · main (MassSpecGym Molecule retrieval) | 5 evaluations · 20 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MassSpecGym · main (MassSpecGym Spectrum simulation) | 4 evaluations · 20 rows | 5 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MassSpecGym de novo generation with formula (bonus), Top-1 Accuracy (MassSpecGym in the Wild Table 9) | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MassSpecGym de novo generation with formula (bonus), Top-1 MCES (MassSpecGym in the Wild Table 9) | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MassSpecGym de novo generation with formula (bonus), Top-1 Tanimoto (MassSpecGym in the Wild Table 9) | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MassSpecGym de novo generation with formula (bonus), Top-10 Accuracy (MassSpecGym in the Wild Table 9) | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MassSpecGym de novo generation with formula (bonus), Top-10 MCES (MassSpecGym in the Wild Table 9) | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MassSpecGym de novo generation with formula (bonus), Top-10 Tanimoto (MassSpecGym in the Wild Table 9) | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MassSpecGym formula-known retrieval (bonus), Hit rate@1 (MassSpecGym in the Wild Table 3) | 18 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MassSpecGym formula-known retrieval (bonus), Hit rate@20 (MassSpecGym in the Wild Table 3) | 18 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MassSpecGym formula-known retrieval (bonus), Hit rate@5 (MassSpecGym in the Wild Table 3) | 18 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MassSpecGym formula-known retrieval (bonus), MCES@1 (MassSpecGym in the Wild Table 3) | 18 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MassSpecGym mass-based retrieval, Hit rate@1 (MassSpecGym in the Wild Table 2) | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MassSpecGym mass-based retrieval, Hit rate@20 (MassSpecGym in the Wild Table 2) | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MassSpecGym mass-based retrieval, Hit rate@5 (MassSpecGym in the Wild Table 2) | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MassSpecGym mass-based retrieval, MCES@1 (MassSpecGym in the Wild Table 2) | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MB brain tumour somatic indels, WGS (Wang et al. 2020 Table S2) | 12 evaluations · 48 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MB brain tumour somatic SNVs, WGS (Wang et al. 2020 Table S1) | 15 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MBNL1-associated junction usage differences across myotonic dystrophy severity groups, held-out genes (SpliceAI2 paper, Pearson) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MCF7 ONT long-read RNA-seq, recovery of 53 known fusions and count of other calls (Dorney et al. 2026) | 6 evaluations · 192 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Mean Spearman over ten regression splits (HyPLM report) | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Median held-out perplexity by position class in Chr5:3,500,000-4,500,000 | 1 evaluation · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Mega-scale dataset stability ranking, Spearman correlation (Chu et al. 2024 Table 1) | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Megascale held-out test split ddG prediction (Dieckhaus et al. 2024 Table 2) | 12 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Meltome human cell (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Meltome mixed (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Metal-ion binding (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Methyltransferase dataset stability ranking, Spearman correlation (Chu et al. 2024 Table 1) | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MFASS splice-disrupting variant detection, all 27,733 labelled SNVs (Znabu et al. 2026) | 5 evaluations · 15 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MFASS v1 (superseded) | 0 evaluations · 0 rows | Not yet available | Superseded record, retained for history. |
| MFASS v2 | 9 evaluations · 31 rows | 4 source-scoped figures | Checked result tables available. |
| MFASS: matched GENCODE 44 canonical annotation | 4 evaluations · 16 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Microglia caQTL effect-size prediction (AlphaGenome paper) | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MIMIC mRNABench probes eCLIP: eCLIP prediction | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MIMIC mRNABench probes GO: GO prediction | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MIMIC mRNABench probes MRL (LBKWK): MRL (LBKWK) prediction | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MIMIC mRNABench probes MRL (Sugimoto): MRL (Sugimoto) prediction | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MIMIC mRNABench probes Protein Localization: Protein Localization prediction | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MIMIC mRNABench probes RNA Half Life: RNA Half Life prediction | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MIMIC mRNABench probes RNA Localization: RNA Localization prediction | 12 evaluations · 12 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Minibinder computational pass rate under TorchScore confidence | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Missense variants splicing-based classification (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MIST CANOPUS retrieval Cos. similarity: MIST CANOPUS fingerprint retrieval: Cos. similarity | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MIST CANOPUS retrieval Top 1: MIST CANOPUS fingerprint retrieval: Top 1 | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MIST CANOPUS retrieval Top 10: MIST CANOPUS fingerprint retrieval: Top 10 | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MIST CANOPUS retrieval Top 100: MIST CANOPUS fingerprint retrieval: Top 100 | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MIST CANOPUS retrieval Top 20: MIST CANOPUS fingerprint retrieval: Top 20 | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MIST CANOPUS retrieval Top 200: MIST CANOPUS fingerprint retrieval: Top 200 | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MIST CANOPUS retrieval Top 5: MIST CANOPUS fingerprint retrieval: Top 5 | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MIST CANOPUS retrieval Top 50: MIST CANOPUS fingerprint retrieval: Top 50 | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Mitochondrial variant pathogenicity classification (Mathur and Sachidanandam 2026 Table 2) | 1 evaluation · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MLH1 curated clinical splicing variants: transcriptome-normalised sensitivity at a 10% background call rate (Smith and Kitzman Table S2) | 8 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MPRabc K562 CRISPRi enhancer–gene evaluation | 6 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| mRNABench Sample designed MRL | 2 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| mRNABench variant probes eCLIP: eCLIP binding site prediction | 50 evaluations · 50 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| mRNABench variant probes GO: Gene Ontology term prediction | 50 evaluations · 50 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| mRNABench variant probes HL: mRNA half life | 50 evaluations · 50 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| mRNABench variant probes MRL-HL-Pair: Paired mean ribosome load and half life | 50 evaluations · 50 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| mRNABench variant probes MRL-MPRA: Mean ribosome load on an MPRA library | 50 evaluations · 50 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| mRNABench variant probes MRL: Mean ribosome load | 50 evaluations · 50 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| mRNABench variant probes Prot-Loc: Protein localisation | 50 evaluations · 50 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| mRNABench variant probes VEP: Variant effect prediction | 50 evaluations · 50 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval MassSpecGym formula split: formula supplied, R@1: MassSpecGym formula split retrieval with formula supplied | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval MassSpecGym formula split: formula supplied, R@20: MassSpecGym formula split retrieval with formula supplied | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval MassSpecGym formula split: formula supplied, R@5: MassSpecGym formula split retrieval with formula supplied | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval MassSpecGym formula split: no formula, R@1: MassSpecGym formula split retrieval with no formula | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval MassSpecGym formula split: no formula, R@20: MassSpecGym formula split retrieval with no formula | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval MassSpecGym formula split: no formula, R@5: MassSpecGym formula split retrieval with no formula | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval MassSpecGym MCES split: formula supplied, R@1: MassSpecGym MCES split retrieval with formula supplied | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval MassSpecGym MCES split: formula supplied, R@20: MassSpecGym MCES split retrieval with formula supplied | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval MassSpecGym MCES split: formula supplied, R@5: MassSpecGym MCES split retrieval with formula supplied | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval MassSpecGym MCES split: no formula, R@1: MassSpecGym MCES split retrieval with no formula | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval MassSpecGym MCES split: no formula, R@20: MassSpecGym MCES split retrieval with no formula | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval MassSpecGym MCES split: no formula, R@5: MassSpecGym MCES split retrieval with no formula | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval NPLIB1: formula supplied, R@1: NPLIB1 retrieval with formula supplied | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval NPLIB1: formula supplied, R@20: NPLIB1 retrieval with formula supplied | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval NPLIB1: formula supplied, R@5: NPLIB1 retrieval with formula supplied | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval NPLIB1: no formula, R@1: NPLIB1 retrieval with no formula | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval NPLIB1: no formula, R@20: NPLIB1 retrieval with no formula | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval NPLIB1: no formula, R@5: NPLIB1 retrieval with no formula | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval Spectraverse: formula supplied, R@1: Spectraverse retrieval with formula supplied | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval Spectraverse: formula supplied, R@20: Spectraverse retrieval with formula supplied | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval Spectraverse: formula supplied, R@5: Spectraverse retrieval with formula supplied | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval Spectraverse: no formula, R@1: Spectraverse retrieval with no formula | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval Spectraverse: no formula, R@20: Spectraverse retrieval with no formula | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign molecular retrieval Spectraverse: no formula, R@5: Spectraverse retrieval with no formula | 6 evaluations · 6 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| MSAlign v2 retrieval: massspecgym-formula-formula-free | 5 evaluations · 15 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MSAlign v2 retrieval: massspecgym-formula-formula-oracle | 4 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MSAlign v2 retrieval: massspecgym-mces-formula-free | 5 evaluations · 15 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MSAlign v2 retrieval: massspecgym-mces-formula-oracle | 4 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MSAlign v2 retrieval: spectraverse-formula-free | 5 evaluations · 15 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MSAlign v2 retrieval: spectraverse-formula-oracle | 4 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MST1R (RON) exon 11 saturation MPSA: transcriptome-normalised sensitivity at a 10% background call rate (Smith and Kitzman Table S2) | 8 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Muse execution on CPU and GPU cloud and DGX machines (O'Connell et al. 2023 Table 1) | 11 evaluations · 42 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Mutated virus mock-community profiling against ground truth (Tisza et al. 2026 Table S9) | 5 evaluations · 75 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Mutect2 execution on CPU and GPU cloud and DGX machines (O'Connell et al. 2023 Table 1) | 11 evaluations · 42 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| MYBPC3 noncanonical splice-site variants: classification against mini- or midigene splicing results (Riepe et al. Table 5) | 11 evaluations · 121 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NA12878 WGS CNV recall and precision, 1 bp overlap (Gabrielaite et al. Table S2) | 8 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Naive against effector CD4 T-cell split within donors, ARI (HyCell report) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Naive against effector CD4 T-cell split, ARI (HyCell report) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Native sequence recovery of designed sequences (HyInv report) | 55 evaluations · 55 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Natural versus GenomeOcean-generated DNA classification (Natural vs artificial microbial genome sequence) | 3 evaluations · 9 rows | 3 source-scoped figures | Checked result tables available.Scope and remaining work
|
| NCH clinically relevant fusion ascertainment | 2 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NLL, held-out UniRef panel (HyPLM report) | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NLL, recent PDB chains (HyPLM report) | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Norman double perturbations: expression prediction for held-out double perturbations (Ahlmann-Eltze et al. 2025 Fig. 1a and Extended Data Fig. 2a) | 9 evaluations · 17 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Norman et al. 2019 Perturb-seq, K562 CRISPRa single and double perturbations: unseen-perturbation expression prediction (Csendes et al. 2025 Supplementary Table 2) | 15 evaluations · 88 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Novel and foldable designs per de novo backbone at matched diversity (HyInv report) | 3 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark Enhancer types, fine-tuning (PEFT) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark Enhancer types, probing | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark Enhancer, fine-tuning (PEFT) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark Enhancer, probing | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H2AFZ, fine-tuning (PEFT) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H2AFZ, probing | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H3K27ac, fine-tuning (PEFT) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H3K27ac, probing | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H3K27me3, fine-tuning (PEFT) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H3K27me3, probing | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H3K36me3, fine-tuning (PEFT) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H3K36me3, probing | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H3K4me1, fine-tuning (PEFT) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H3K4me1, probing | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H3K4me2, fine-tuning (PEFT) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H3K4me2, probing | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H3K4me3, fine-tuning (PEFT) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H3K4me3, probing | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H3K9ac, fine-tuning (PEFT) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H3K9ac, probing | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H3K9me3, fine-tuning (PEFT) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H3K9me3, probing | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H4K20me1, fine-tuning (PEFT) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark H4K20me1, probing | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark normalised summed performance (Supplementary Table 9) | 23 evaluations · 23 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark Promoter all, fine-tuning (PEFT) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark Promoter all, probing | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark Promoter non-TATA, fine-tuning (PEFT) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark Promoter non-TATA, probing | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark Promoter TATA, fine-tuning (PEFT) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark Promoter TATA, probing | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark Splice acceptor, fine-tuning (PEFT) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark Splice acceptor, probing | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark Splice donor, fine-tuning (PEFT) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark Splice donor, probing | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark Splice site all, fine-tuning (PEFT) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT benchmark Splice site all, probing | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT-splice-sites-acceptors splice-site classification, fine-tuned models (You et al. 2026 Supplementary Table 4) | 11 evaluations · 44 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT-splice-sites-all splice-site classification, fine-tuned models (You et al. 2026 Supplementary Table 4) | 11 evaluations · 44 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NT-splice-sites-donors splice-site classification, fine-tuned models (You et al. 2026 Supplementary Table 4) | 11 evaluations · 44 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| NTv3 H100 GPU-hours per training stage (Boshar et al. 2025 Table 5) | 3 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Nucleotide Transformer benchmark under frozen-embedding probing (Datta et al. 2026 Table 1) | 72 evaluations · 72 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Nucleotide Transformer benchmark, reference fine-tuned scores (Datta et al. 2026 Table 1) | 72 evaluations · 72 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Nucleotide Transformer IA3 fine-tuning run time (Dalla-Torre et al. 2025 Methods 'Hardware') | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| OAK overall survival, Uno C-index of a predictor fitted on other cohorts | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| OGBl-ppa PPI link prediction, Accuracy (Table 6) | 77 evaluations · 77 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| OGBl-ppa PPI link prediction, Hits@100 (Table 5) | 77 evaluations · 77 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| OMIM pathogenic vs gnomAD common regulatory variants, AUPRC (GPN-MSA Supplementary Table 4) | 17 evaluations · 34 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| OMIM pathogenic vs gnomAD common regulatory variants, AUPRC (GPN-Star Supplementary Table 3) | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10) | 17 evaluations · 85 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9) | 33 evaluations · 165 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions | 1 evaluation · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| OncoVI three-class assessment: Erlangen MTB variants | 1 evaluation · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| OncoVI three-class assessment: Guideline SOP variants | 1 evaluation · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| OncoVI three-class assessment: MTB selected expert reassessment | 2 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ONT COLO829 tumour-only, 25x to 75x, somatic indels (Chen et al. 2025 Supplementary Table 2a) | 4 evaluations · 84 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ONT COLO829 tumour-only, 25x to 75x, somatic SNVs (Chen et al. 2025 Supplementary Table 2a) | 4 evaluations · 84 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ONT HCC1395 tumour-only, 25x to 75x, somatic indels (Chen et al. 2025 Supplementary Table 2b) | 3 evaluations · 63 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ONT HCC1395 tumour-only, 25x to 75x, somatic SNVs (Chen et al. 2025 Supplementary Table 2b) | 3 evaluations · 63 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ONT Q20 ZymoBIOMICS D6300 standard, length-filtered (PromethION): species detection at 0.001% of total reads (Portik et al. 2022 Table 4) | 14 evaluations · 112 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ONT R10.3 ZymoBIOMICS D6300 standard, length-filtered (GridION): species detection at 0.001% of total reads (Portik et al. 2022 Table 4) | 14 evaluations · 112 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| OpenSplice MPRA delta PSI prediction for 283,121 single-nucleotide substitutions in 599 exons (SpliceAI2 paper, Spearman) | 4 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) | 2 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Organism-level agreement with composite reference standard (CRS), 62 BALF specimens (Hu et al. 2026) | 2 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Organism-level agreement with routine culture, 62 BALF specimens (Hu et al. 2026) | 2 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| OUTRIDER expression z-score at 16 known pathogenic splicing events in muscle RNA-seq (Segarra-Casas et al. Table 2) | 1 evaluation · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PacBio HiFi COLO829 tumour-only, 50x, somatic indels (Chen et al. 2025 Supplementary Table 7a) | 4 evaluations · 28 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PacBio HiFi COLO829 tumour-only, 50x, somatic SNVs (Chen et al. 2025 Supplementary Table 7a) | 4 evaluations · 28 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Paediatric B-ALL nanopore WTS, high-depth cohort, dominant-fusion classification (Lin et al. 2026 Table 3) | 4 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Paediatric B-ALL nanopore WTS, low-depth cohort, dominant-fusion classification (Lin et al. 2026 Table 6) | 4 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Paired scTM difference from HyInv under Boltz2 (HyInv report) | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Paired scTM difference from HyInv under ESMFold2 (HyInv report) | 50 evaluations · 50 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Paired scTM difference from HyInv under Protenix2 (HyInv report) | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Pan_dataset five-fold PPI cross-validation (protein-protein interaction prediction) | 3 evaluations · 15 rows | 5 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Paper-specific Plinder-L95 stereochemistry assessment; Table 1 all entries · Plinder-L95 · co-folding | 5 evaluations · 25 rows | 5 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Paper-specific Plinder-L95 stereochemistry assessment; Table 1 all entries · Plinder-L95 · docking with ground-truth-centred search box | 1 evaluation · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Paper-specific Plinder-L95 stereochemistry assessment; Table 1 all entries · Plinder-L95 · rigid-receptor docking | 1 evaluation · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Parabricks DeepVariant v4.1.0-1 versus v4.3.0-1 on 8 H100 GPUs (Samarakoon et al. 2025 Table S4) | 2 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Patient-level detection of causative pathogens in blood against the final clinical diagnosis (Huang et al. 2026 Table 2) | 4 evaluations · 80 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PBMC deconvolution, pairwise ordering accuracy, mean over five lineages | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PBMC deconvolution, Pearson r of inferred against measured shares, mean over five lineages | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PBMC deconvolution, per-lineage Pearson r of inferred against measured shares | 2 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PCAWG ten primary tumours, tumour-only SNVs, AUPRC (Krishnamachari et al. 2026 Supplementary Table 2) | 9 evaluations · 90 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PDB (RNA secondary structure) | 10 evaluations · 40 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PDBbind-2016 core set (Protein–ligand binding affinity scoring) | 9 evaluations · 18 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Peak memory under 8-bit and 4-bit quantization relative to BF16 (Saadat and Fellay 2026 Figure 5) | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PepSpecBench A. thaliana OOD subset, median SA | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PepSpecBench A. thaliana OOD subset, median SAS | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PepSpecBench C. elegans OOD subset, median SA | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PepSpecBench C. elegans OOD subset, median SAS | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PepSpecBench E. coli OOD subsets (both sources aggregated), median SA | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PepSpecBench E. coli OOD subsets (both sources aggregated), median SAS | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PepSpecBench HeLa OOD subset, median SA | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PepSpecBench HeLa OOD subset, median SAS | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PepSpecBench MassIVE-KB-Mini test split, median PCC | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PepSpecBench MassIVE-KB-Mini test split, median SA | 6 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PepSpecBench MassIVE-KB-Mini test split, median SAS | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PepSpecBench PROSPECT-Mini test split, median PCC | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PepSpecBench PROSPECT-Mini test split, median SA | 6 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PepSpecBench PROSPECT-Mini test split, median SAS | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PepSpecBench Yeast OOD subset, median SA | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PepSpecBench Yeast OOD subset, median SAS | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PertEval-scFM Norman single-gene (2,000 HVGs) AUSPC across SPECTRA sparsification splits | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Perturbation-first AUROC, K562 CRISPRa (Kendiukhov 2026) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Perturbation-first AUROC, K562 CRISPRi (Kendiukhov 2026) | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Perturbation-first AUROC, RPE1 CRISPRi (Kendiukhov 2026) | 9 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Perturbation-first AUROC, RPE1 CRISPRi restricted to the top 2,000 HVGs (Kendiukhov 2026) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PerturBench v4 combination prediction of held-out dual perturbations on Norman19 | 11 evaluations · 67 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PerturBench v4 covariate transfer from mono-culture to co-culture on Frangieh21 | 10 evaluations · 63 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PerturBench v4 covariate transfer of small-molecule effects across PBMC cell types on OP3 | 8 evaluations · 55 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PerturBench v4 covariate transfer to a held-out cell line on Srivatsan20 | 11 evaluations · 67 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PerturBench v4 covariate transfer to held-out perturbations in held-out biological states on Jiang24 | 7 evaluations · 48 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PerturBench v4 mode-collapse diagnostics on Frangieh21 | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PerturBench v4 mode-collapse diagnostics on Srivatsan20 | 5 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PerturbPFN in-prior latent recovery on held-out synthetic episodes (Table 1) | 1 evaluation · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PGB promoter strength maize protoplasts: A. thaliana: promoter strength prediction | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PGB promoter strength maize protoplasts: S. bicolor: promoter strength prediction | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PGB promoter strength maize protoplasts: Z. mays: promoter strength prediction | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PGB promoter strength tobacco leaves: A. thaliana: promoter strength prediction | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PGB promoter strength tobacco leaves: S. bicolor: promoter strength prediction | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PGB promoter strength tobacco leaves: Z. mays: promoter strength prediction | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PGB terminator strength maize protoplasts: A. thaliana: terminator strength prediction | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PGB terminator strength maize protoplasts: randomized GC sequences: terminator strength prediction | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PGB terminator strength maize protoplasts: Z. mays: terminator strength prediction | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PGB terminator strength tobacco leaves: A. thaliana: terminator strength prediction | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PGB terminator strength tobacco leaves: randomized GC sequences: terminator strength prediction | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| PGB terminator strength tobacco leaves: Z. mays: terminator strength prediction | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Picking the top AlphaFold3 model per antibody-antigen target with a confidence score | 9 evaluations · 27 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PLABench CASP16 L1000 affinity | 9 evaluations · 54 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PLABench CASP16 L3000 affinity | 9 evaluations · 54 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PLABench ChEMBL35 leakage-controlled affinity | 9 evaluations · 63 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PLABench Davis, cold-drug split | 3 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PLABench Davis, cold-target split | 3 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PLABench Davis, warm split | 3 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PLABench KIBA, cold-drug split | 3 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PLABench KIBA, cold-target split | 3 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PLABench KIBA, warm split | 3 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| pLDDT of ESMFold2 predictions of designed sequences (HyInv report) | 60 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| POISK 1-in-50 screening simulation, top-1 retrieval | 6 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| POISK 1-in-50 screening simulation, top-10 retrieval | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| POISK binder-decoy separation in full-Fv ipSAE, Cohen's d | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| POISK binder-decoy separation in ipTM, Cohen's d | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| POISK epitope contact recovery | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| POISK pair coverage under cross-model structural consensus | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| POISK pairs left undecidable by identical ipSAE | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| POISK pairwise binder-versus-decoy accuracy at 10% coverage | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| POISK pairwise binder-versus-decoy accuracy at 100% coverage | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| POISK pairwise binder-versus-decoy accuracy at 25% coverage | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| POISK pairwise binder-versus-decoy accuracy at 50% coverage | 6 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| POISK pairwise binder-versus-decoy accuracy at 75% coverage | 6 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| POISK pairwise binder-versus-decoy accuracy under cross-model structural consensus | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Polyadenylation-QTL causality (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Positive-control virus detection by read depth (Tisza et al. 2026 Table S2) | 5 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| POU1F1 exon 2 saturation MPSA: transcriptome-normalised sensitivity at a 10% background call rate (Smith and Kitzman Table S2) | 8 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PP3/BP4 score intervals on the points scale (Bergquist et al. 2025 Table 1) | 7 evaluations · 63 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PP3/BP4 score intervals per evidence strength (Pejaver et al. 2022 Table 2) | 13 evaluations · 104 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predicted affinity of designed ligand pockets | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Predictive sensitivity, day -3 to -1 (Wolf et al. 2026 Table 2) | 1 evaluation · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive specificity in control samples (Wolf et al. 2026 Table 3) | 2 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive-class counts for dimeric predictions, all structures in the class (Table 2, column 'No.') | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive-class counts for dimeric predictions, heterodimeric structures in the class (Table 2, column 'Heterodimer') | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive-class counts for dimeric predictions, homodimeric structures in the class (Table 2, column 'Homodimer') | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive-class counts for dimeric predictions, structures in the class whose experimental reference is electron microscopy (Table 2, column 'EM') | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive-class counts for dimeric predictions, structures in the class whose experimental reference is NMR (Table 2, column 'NMR') | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive-class counts for dimeric predictions, structures in the class whose experimental reference is X-ray diffraction (Table 2, column 'XRD') | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive-class counts for dimeric predictions, structures in the class whose pLDDT is at least 70 (Table 2, column 'pLDDT ≥ 70') | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive-class counts for dimeric predictions, structures in the class with template quality 0 (no homologous pre-2022 structure) (Table 2, column 'TQ 0') | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive-class counts for dimeric predictions, structures in the class with template quality above 40 (Table 2, column 'TQ > 40') | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive-class counts for dimeric predictions, structures in the class with template quality between 1 and 40 (Table 2, column 'TQ 1–40') | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive-class counts for monomeric predictions, all structures in the class (Table 1, column 'No.') | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive-class counts for monomeric predictions, structures in the class whose experimental reference is electron microscopy (Table 1, column 'EM') | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive-class counts for monomeric predictions, structures in the class whose experimental reference is NMR (Table 1, column 'NMR') | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive-class counts for monomeric predictions, structures in the class whose experimental reference is X-ray diffraction (Table 1, column 'XRD') | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive-class counts for monomeric predictions, structures in the class whose pLDDT is at least 70 (Table 1, column 'pLDDT ≥ 70') | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive-class counts for monomeric predictions, structures in the class with template quality 0 (no homologous pre-2022 structure) (Table 1, column 'TQ 0') | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive-class counts for monomeric predictions, structures in the class with template quality above 40 (Table 1, column 'TQ > 40') | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Predictive-class counts for monomeric predictions, structures in the class with template quality between 1 and 40 (Table 1, column 'TQ 1–40') | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Pretraining GPUs and runtime for short-range models (HyenaDNA Table A.2) | 4 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PRIME ACE2 binding regression, Position-stratified split holding out whole mutated positions, R² | 21 evaluations · 21 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PRIME ACE2 binding regression, Position-stratified split holding out whole mutated positions, RMSE | 21 evaluations · 21 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PRIME ACE2 binding regression, Random split over RBD mutants, R² | 21 evaluations · 21 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PRIME ACE2 binding regression, Random split over RBD mutants, RMSE | 21 evaluations · 21 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PRIME RBD expression regression, Position-stratified split holding out whole mutated positions, R² | 21 evaluations · 21 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PRIME RBD expression regression, Position-stratified split holding out whole mutated positions, RMSE | 21 evaluations · 21 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PRIME RBD expression regression, Random split over RBD mutants, R² | 21 evaluations · 21 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PRIME RBD expression regression, Random split over RBD mutants, RMSE | 21 evaluations · 21 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PRO-cap prediction on held-out peaks (AlphaGenome paper) | 2 evaluations · 4 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Project Score target-priority scoring v2.0 | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Propensity-matched edge AUROC (Kendiukhov 2026) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Protective-antigen classification feature comparison (vaccine-antigen candidate prediction) | 3 evaluations · 21 rows | 7 source-scoped figures | Checked result tables available.Scope and remaining work
|
| ProteinGym AMFR official zero-shot Spearman snapshot | 97 evaluations · 97 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ProteinGym clinical indels, zero-shot, average AUC (commit 144fe22) | 18 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ProteinGym clinical substitutions, supervised predictors, average AUC (commit 144fe22) | 17 evaluations · 17 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ProteinGym clinical substitutions, zero-shot, average AUC (commit 144fe22) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ProteinGym DMS TADBP binary classification, AUROC (GPN-MSA paper) | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ProteinGym human deep mutational scanning, mean Spearman (GPN-Star Supplementary Table 3) | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ProteinGym v1.3 AMFR seeded-random control | 1 evaluation · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ProteinGym v1.3 AMFR substitution assay | 1 evaluation · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ProteinGym v1.3 zero-shot DMS substitutions | 97 evaluations · 1,746 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ProteinGym zero-shot (HyPLM report) | 17 evaluations · 17 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ProteinGym zero-shot paired difference from HyPLM-Flash (HyPLM report) | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ProteinGym zero-shot, activity assays (HyPLM report) | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ProteinGym zero-shot, binding assays (HyPLM report) | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ProteinGym zero-shot, expression assays (HyPLM report) | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ProteinGym zero-shot, organismal fitness assays (HyPLM report) | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ProteinGym zero-shot, stability assays (HyPLM report) | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Pseudo-perplexity agreement between reference and efficient implementations (Saadat and Fellay 2026 Figure 1) | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| PTEN dataset stability ranking, Spearman correlation (Chu et al. 2024 Table 1) | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Public FEP benchmark, FEP+ accuracy against experiment | 1 evaluation · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Rank of known disease genes in 12 Kremer fibroblast RNA samples, aberrant expression (Segers et al. Table 2) | 4 evaluations · 48 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Rank of known disease genes in 12 Kremer fibroblast RNA samples, aberrant splicing (Segers et al. Table 2) | 3 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ranking the causative gene within synthetic candidate sets of 5 to 100 genes, ClinVar (Kafkas et al. 2025 Table 3) | 3 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ranking the causative gene within synthetic candidate sets of 5 to 100 genes, GPCards (Kafkas et al. 2025 Table 3) | 2 evaluations · 40 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ranking the causative gene within synthetic candidate sets of 5 to 100 genes, PAVS (Kafkas et al. 2025 Table 3) | 3 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Rare complex-trait SNVs versus matched controls, AUPRC (AlphaGenome Atlas) | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Rare versus common variant enrichment in the lowest 0.1% of scores, 1001 Genomes | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Re-ranking the AmpC beta-lactamase docking hit list by co-folding and docking scores (Kim, Correy, Hall et al. 2026) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Re-ranking the Dopamine D4 receptor docking hit list by co-folding and docking scores (Kim, Correy, Hall et al. 2026) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Re-ranking the Sigma-2 receptor docking hit list by co-folding and docking scores (Kim, Correy, Hall et al. 2026) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Read classification on 30 ONT pseudo-mock communities of out-of-database species (Peres da Silva et al. 2024) | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| real_test PPI held-out evaluation (protein-protein interaction prediction) | 3 evaluations · 18 rows | 6 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Recovery of known allelic-imbalance genes and outlier calls in true-negative samples, patient muscle RNA-seq (Silverstein et al. Table S9, ANEVA-H and MAE) | 2 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Recovery of known expression-outlier genes and outlier calls in true-negative samples, patient RNA-seq (Silverstein et al. Table S9, OUTRIDER) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Recovery of known pathogenic splicing events and outlier calls in true-negative samples, patient RNA-seq (Silverstein et al. Table S9, splicing tools) | 5 evaluations · 45 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Relative abundance of each species in ZymoBIOMICS Standard II against its theoretical distribution (Song et al. 2025 Table 1) | 4 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Relative abundance of viridans group streptococci in culture-positive patient blood and negative controls (Song et al. 2025 Table 2) | 4 evaluations · 28 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Remote homology (fold) (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Repeat-assay reproducibility of relative binding free energies | 1 evaluation · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Replogle et al. 2022 genome-wide Perturb-seq subset, K562 CRISPRi: unseen-perturbation expression prediction (Csendes et al. 2025 Supplementary Table 2) | 15 evaluations · 88 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Replogle et al. 2022 genome-wide Perturb-seq subset, RPE1 CRISPRi: unseen-perturbation expression prediction (Csendes et al. 2025 Supplementary Table 2) | 15 evaluations · 88 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Replogle K562: expression prediction for unseen single perturbations (Ahlmann-Eltze et al. 2025 Fig. 2a and Extended Data Fig. 8a) | 7 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Replogle RPE1: expression prediction for unseen single perturbations (Ahlmann-Eltze et al. 2025 Fig. 2a and Extended Data Fig. 8a) | 7 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Respiratory virus detection against PCR, family level, read-count cut-off 0 (Carbo et al. 2022 Supplementary Table 1) | 15 evaluations · 165 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Respiratory virus detection against PCR, genus level, read-count cut-off 0 (Carbo et al. 2022 Supplementary Table 1) | 15 evaluations · 165 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Respiratory virus detection against PCR, species level, read-count cut-off 0 (Carbo et al. 2022 Supplementary Table 1) | 15 evaluations · 165 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Respiratory virus detection against PCR, species level, read-count cut-off 10 (Carbo et al. 2022 Supplementary Table 1) | 15 evaluations · 165 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Retrospective active learning on a fully measured two-gene CRISPR viability screen: top-200 gene pairs found by round 4 | 5 evaluations · 152 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Rfam12.3–14.10 (RNA secondary structure) | 10 evaluations · 40 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| RhoFold+ 2024 CASP15 natural RNA comparison R1107-rmsd: R1107: RMSD | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| RhoFold+ 2024 CASP15 natural RNA comparison R1107-sum_z_gdt_ts_tm_score: R1107: Sum of Z-scores for GDT-TS and TM-score | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| RhoFold+ 2024 CASP15 natural RNA comparison R1108-rmsd: R1108: RMSD | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| RhoFold+ 2024 CASP15 natural RNA comparison R1108-sum_z_gdt_ts_tm_score: R1108: Sum of Z-scores for GDT-TS and TM-score | 8 evaluations · 8 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| RhoFold+ 2024 CASP15 natural RNA comparison R1116-rmsd: R1116: RMSD | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| RhoFold+ 2024 CASP15 natural RNA comparison R1116-sum_z_gdt_ts_tm_score: R1116: Sum of Z-scores for GDT-TS and TM-score | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| RhoFold+ 2024 CASP15 natural RNA comparison R1117-rmsd: R1117: RMSD | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| RhoFold+ 2024 CASP15 natural RNA comparison R1117-sum_z_gdt_ts_tm_score: R1117: Sum of Z-scores for GDT-TS and TM-score | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| RhoFold+ 2024 CASP15 natural RNA comparison R1149-rmsd: R1149: RMSD | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| RhoFold+ 2024 CASP15 natural RNA comparison R1149-sum_z_gdt_ts_tm_score: R1149: Sum of Z-scores for GDT-TS and TM-score | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| RhoFold+ 2024 CASP15 natural RNA comparison R1156-rmsd: R1156: RMSD | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| RhoFold+ 2024 CASP15 natural RNA comparison R1156-sum_z_gdt_ts_tm_score: R1156: Sum of Z-scores for GDT-TS and TM-score | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| RhoMax WT-background holdout mean | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RhoMax WT-background holdout split 1 | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RhoMax WT-background holdout split 2 | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RhoMax WT-background holdout split 3 | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RhoMax WT-background holdout split 4 | 3 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RNA expression correlation across genes (AlphaGenome paper) | 2 evaluations · 4 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| RNA expression correlation across tracks (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| RNA-seq confirmation of SpliceAI2-prioritised rare variants in panel genes, Genomics England rare-disease participants (SpliceAI2 paper) | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RNA-seq track prediction at 32 bp (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| RNAGym v0.1.1 fitness, signed Spearman, Aptamer | 16 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RNAGym v0.1.1 fitness, signed Spearman, macro over 3 ncRNA categories | 16 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RNAGym v0.1.1 fitness, signed Spearman, Ribozyme | 16 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RNAGym v0.1.1 fitness, signed Spearman, tRNA | 16 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RVDB 33-class viral classification by nearest-neighbour retrieval over frozen embeddings (Bůžková et al. 2026 Table 3) | 36 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RVDB long-sequence viral classification, 16 classes (Bůžková et al. 2026 Table 10) | 5 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| RVDB viral classification: best frozen-embedding configuration against BLAST (Bůžková et al. 2026 Table 7) | 6 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| S669 direct and reverse ddG prediction (Pancotti et al. 2022 Table 1) | 21 evaluations · 231 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| S669 direct ddG prediction (Dieckhaus et al. 2024 Table 3) | 13 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Scaffold-Lab unconditional generation: Ci | 28 evaluations · 28 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Scaffold-Lab unconditional generation: Designability(↑) | 28 evaluations · 28 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Scaffold-Lab unconditional generation: Diversity (↑) | 28 evaluations · 28 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Scaffold-Lab unconditional generation: Efficiency (↓) | 28 evaluations · 28 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Scaffold-Lab unconditional generation: Mean Ci | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Scaffold-Lab unconditional generation: Novelty(↓) | 28 evaluations · 28 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Scaffold-Lab unconditional generation: Rank | 10 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| scFoundation cell-type annotation comparison Segerstolpe: Segerstolpe cell-type annotation | 7 evaluations · 7 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| scFoundation cell-type annotation comparison Zheng68K: Zheng68K cell-type annotation | 7 evaluations · 7 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Sci-Plex highest-dose holdout with min-max normalised MD, Pearson r and W2 (PerturbPFN Table 2) | 7 evaluations · 41 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| scIB batch correction (HyCell report) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| scIB biological conservation (HyCell report) | 55 evaluations · 55 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| scIB official RNA metrics export · pancreas | 69 evaluations · 821 rows | 13 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SCMBench paired RNA-ATAC integration accuracy | 128 evaluations · 128 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SCMBench unpaired RNA-ATAC integration accuracy | 113 evaluations · 113 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| scTab deep-ensemble uncertainty ROC-AUC: known-type correct vs. incorrect (Group 1 vs. Group 2) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| scTab deep-ensemble uncertainty ROC-AUC: known-type vs. absent-type (Group 1 vs. Group 3) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| scTab Table 1a: seeded model fits | 11 evaluations · 11 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| scTab Table 1b: seeded fits plus donor bootstrap | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| scTab Table 2 hardware-specific resources | 5 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| scTM at fixed sequence diversity on the development panel (HyInv report) | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| scTM of designed sequences under Boltz2 (HyInv report) | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| scTM of designed sequences under ESMFold2 (HyInv report) | 60 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| scTM of designed sequences under Protenix2 (HyInv report) | 12 evaluations · 12 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Secondary structure (CB513) (HyPLM report) | 14 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SegmentNT human genome annotation 3UTR auPRC: 3UTR: per-nucleotide annotation (auPRC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation 3UTR MCC: 3UTR: per-nucleotide annotation (MCC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation 5UTR auPRC: 5UTR: per-nucleotide annotation (auPRC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation 5UTR MCC: 5UTR: per-nucleotide annotation (MCC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation CTCF-bound auPRC: CTCF-bound: per-nucleotide annotation (auPRC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation CTCF-bound MCC: CTCF-bound: per-nucleotide annotation (MCC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation enhancer tissue-invariant auPRC: enhancer tissue-invariant: per-nucleotide annotation (auPRC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation enhancer tissue-invariant MCC: enhancer tissue-invariant: per-nucleotide annotation (MCC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation enhancer tissue-specific auPRC: enhancer tissue-specific: per-nucleotide annotation (auPRC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation enhancer tissue-specific MCC: enhancer tissue-specific: per-nucleotide annotation (MCC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation exon auPRC: exon: per-nucleotide annotation (auPRC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation exon MCC: exon: per-nucleotide annotation (MCC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation intron auPRC: intron: per-nucleotide annotation (auPRC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation intron MCC: intron: per-nucleotide annotation (MCC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation lncRNA auPRC: lncRNA: per-nucleotide annotation (auPRC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation lncRNA MCC: lncRNA: per-nucleotide annotation (MCC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation polyA signal auPRC: polyA signal: per-nucleotide annotation (auPRC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation polyA signal MCC: polyA signal: per-nucleotide annotation (MCC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation promoter tissue-invariant auPRC: promoter tissue-invariant: per-nucleotide annotation (auPRC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation promoter tissue-invariant MCC: promoter tissue-invariant: per-nucleotide annotation (MCC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation promoter tissue-specific auPRC: promoter tissue-specific: per-nucleotide annotation (auPRC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation promoter tissue-specific MCC: promoter tissue-specific: per-nucleotide annotation (MCC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation protein coding gene auPRC: protein coding gene: per-nucleotide annotation (auPRC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation protein coding gene MCC: protein coding gene: per-nucleotide annotation (MCC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation splice acceptor auPRC: splice acceptor: per-nucleotide annotation (auPRC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation splice acceptor MCC: splice acceptor: per-nucleotide annotation (MCC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation splice donor auPRC: splice donor: per-nucleotide annotation (auPRC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SegmentNT human genome annotation splice donor MCC: splice donor: per-nucleotide annotation (MCC) | 21 evaluations · 21 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Self-consistency RMSD of designed sequences under ESMFold2 (HyInv report) | 60 evaluations · 60 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SEQC2 HCC1395 library preparation and DNA input, indel F1 (Sahraeian et al. 2022 Table S4) | 15 evaluations · 105 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SEQC2 HCC1395 library preparation and DNA input, SNV F1 (Sahraeian et al. 2022 Table S4) | 17 evaluations · 119 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2) | 15 evaluations · 330 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SEQC2 HCC1395 sequencing centre and platform, SNV F1 (Sahraeian et al. 2022 Table S2) | 17 evaluations · 374 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, indel F1 (Sahraeian et al. 2022 Table S3) | 15 evaluations · 720 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SEQC2 HCC1395 tumour purity, coverage and normal contamination, SNV F1 (Sahraeian et al. 2022 Table S3) | 17 evaluations · 816 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SEQC2 HCC1395 tumour-only, indels, AUPRC (Krishnamachari et al. 2026 Supplementary Table 1) | 9 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SEQC2 HCC1395 tumour-only, SNVs, AUPRC (Krishnamachari et al. 2026 Supplementary Table 1) | 9 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SEQC2 HCC1395 WES validation sample, somatic indels (Guille et al. 2025 Table S7) | 15 evaluations · 90 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SEQC2 HCC1395 WES validation sample, somatic SNVs (Guille et al. 2025 Table S7) | 18 evaluations · 108 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Sequence diversity of a design set (HyInv report) | 55 evaluations · 55 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SF3B1-associated junction usage differences in uveal melanoma, held-out genes (SpliceAI2 paper, Pearson) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SGE held-out screens pooled, functionally abnormal versus normal SNVs, AUPRC (AlphaGenome Atlas) | 7 evaluations · 7 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SGE held-out screens pooled, SNVs and indels, AUPRC (AlphaGenome Atlas) | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Share of further OPA1 pathogenic substitutions and VUS called splice-altering (Alavi Table III, extended corpus) | 13 evaluations · 26 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Share of gnomAD variants called pathogenic at developer thresholds (Pejaver et al. 2022 Table 3) | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Share of simulated repeat variants scored below the first decile of missense variants | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Simulated long-read fusion detection, 400 fusions at three depths and three read identities (Dorney et al. 2026) | 6 evaluations · 250 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SJC test split (protein-small molecule binding-site prediction) | 4 evaluations · 16 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| So 2024 VarSome-vs-CanVIG-UK agreement on conflicting BRCA1 missense variants | 1 evaluation · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SomaticSniper execution on CPU and GPU cloud and DGX machines (O'Connell et al. 2023 Table 1) | 11 evaluations · 42 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Species profiling on Dilthey2019 simulated long reads (Long-read taxonomic profiling) | 7 evaluations · 21 rows | 3 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Speed-up of a design request over ProteinMPNN on one NVIDIA H20 (HyInv report) | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SPI1 binding QTL classification (AlphaGenome paper) | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SPI1 binding QTL effect-size prediction (AlphaGenome paper) | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Splice-altering variant classification, Barbosa et al. ClinVar intronic SNV benchmark (53,600 variants) (Fortier et al. Table 5) | 4 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Splice-altering variant classification, Barbosa et al. deep intronic pathogenic variants with matched common controls (484 variants) (Fortier et al. Table 4) | 4 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Splice-altering variant classification, CI-SpliceAI benchmark variant set (1,316 variants) (Fortier et al. Table 1) | 4 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Splice-altering variant classification, Extended ClinVar benchmark (58,064 variants) (Fortier et al. Table 6) | 4 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Splice-altering variant classification, Riepe et al. functional splice assay variants (213 variants, ABCA4 and MYBPC3) (Fortier et al. Table 2) | 4 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Splice-altering variant classification, SPiP benchmark variant set (99,601 variants) (Fortier et al. Table 3) | 4 evaluations · 16 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Splice-defect classification of OPA1 variants with thresholds tuned on the same sets (Alavi Table III, evaluation sets) | 13 evaluations · 78 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Splice-effect prediction against patient-RNA or exon-trapping results, all 243 scorable variants (Drost et al. Data S1) | 8 evaluations · 56 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Splice-effect prediction against patient-RNA or exon-trapping results, CAGI6 Splicing VUS subset (Drost et al. Data S1) | 8 evaluations · 56 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Splice-effect prediction against patient-RNA or exon-trapping results, in-house diagnostic cohort (Drost et al. Data S1) | 8 evaluations · 56 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Splice-site-region variants splicing-based classification (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Spliceogenic versus benign classification on an independent 65-gene set with OPA1-derived thresholds (Alavi Table IV) | 13 evaluations · 78 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Splicing-QTL causality (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SPOT-MAS five-class tissue of origin, discovery cohort 10-fold cross-validation | 3 evaluations · 66 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SPOT-MAS five-class tissue of origin, independent validation cohort | 3 evaluations · 66 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ssym direct and inverse ddG prediction (Dieckhaus et al. 2024 Table 3) | 13 evaluations · 50 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Stability (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| SugarBase immunogenicity · Immuno (GlycanML immunogenicity prediction) | 10 evaluations · 10 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SugarBase taxonomy · Class (GlycanML taxonomy prediction) | 22 evaluations · 22 rows | 3 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SugarBase taxonomy · Domain (GlycanML taxonomy prediction) | 22 evaluations · 22 rows | 3 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SugarBase taxonomy · Family (GlycanML taxonomy prediction) | 22 evaluations · 22 rows | 3 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SugarBase taxonomy · Genus (GlycanML taxonomy prediction) | 22 evaluations · 22 rows | 3 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SugarBase taxonomy · Kingdom (GlycanML taxonomy prediction) | 22 evaluations · 22 rows | 3 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SugarBase taxonomy · Mean Acc (GlycanML taxonomy prediction) | 14 evaluations · 14 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SugarBase taxonomy · Order (GlycanML taxonomy prediction) | 22 evaluations · 22 rows | 3 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SugarBase taxonomy · Phylum (GlycanML taxonomy prediction) | 22 evaluations · 22 rows | 3 source-scoped figures | Checked result tables available.Scope and remaining work
|
| SugarBase taxonomy · Species (GlycanML taxonomy prediction) | 22 evaluations · 22 rows | 3 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Sun et al. 2024 five-cancer detection from deconvolved plasma cfMethyl-Seq (ROC-AUC per cancer type) | 5 evaluations · 25 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Sun et al. 2024 liver cancer detection from deconvolved plasma WGBS (ROC-AUC) | 5 evaluations · 5 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Sun et al. 2026 cellular-context DE classification (cross cell line) | 45 evaluations · 90 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Sun et al. 2026 unseen-perturbation DE classification (within cell line) | 40 evaluations · 80 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Supervised distance-balanced eQTL causality (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Supervised enhancer–gene linking (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Supervised GTEx splicing-outlier prediction (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Supervised multimodal CAGI5 MPRA prediction (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Survival transfer CPTAC to TCGA, mean Uno C-index over six cancers | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Survival transfer TCGA and CPTAC, pan-cancer Uno C-index, mean of two directions | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Survival transfer TCGA to CPTAC, mean Uno C-index over six cancers | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Synthetic WES tumour-normal pair, 4,709 inserted COSMIC SNVs (López-Cade et al. 2025 Table 1) | 3 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Talos diagnosis recovery and workload: ACG full | 2 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Talos diagnosis recovery and workload: ACG singleton | 2 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Talos diagnosis recovery and workload: ACG trio | 2 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Talos diagnosis recovery and workload: RGP full | 2 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Talos diagnosis recovery and workload: RGP singleton | 2 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Talos diagnosis recovery and workload: RGP trio | 2 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Talos programme reanalysis yield | 1 evaluation · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Talos recovery of known P/LP and VUS variants in 162 trio cases (Kaschta et al. 2026) | 2 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Talos recovery of known P/LP and VUS variants in 45 singleton cases (Kaschta et al. 2026) | 1 evaluation · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Target-level detection of respiratory pathogens against routine multiplex PCR, validation set (Sanderson et al. 2026) | 2 evaluations · 14 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Telling cognate from shuffled nanobody-antigen pairs by ipTM | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Test perplexity on Arabidopsis thaliana chromosome 5, chromosome-wide | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Test perplexity on Arabidopsis thaliana chromosome 5, non-repeat regions | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TF ChIP-seq track prediction at 128 bp (AlphaGenome paper) | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TF ChIP-seq track prediction at 32 bp (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| TF-cell-type binding on held-out chromosomes8and9 (transcription-factor DNA binding-site prediction) | 6 evaluations · 12 rows | 2 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Thermostability (HyPLM report) | 13 evaluations · 13 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Three-category CNV classification, per-class agreement on deletions (Zhang et al. Table 4, DEL) | 5 evaluations · 15 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Three-category CNV classification, per-class agreement on duplications (Zhang et al. Table 4, DUP) | 5 evaluations · 15 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Tissue-specific junction usage differences across GTEx tissue pairs, held-out chromosomes (SpliceAI2 paper, Pearson) | 1 evaluation · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TorchCraft runtime per design at 100 residues | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TorchCraft runtime per design at 200 residues | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TorchCraft runtime per design at 300 residues | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TorchCraft runtime per design at 400 residues | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TorchCraft runtime per design at 500 residues | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Training peak GPU memory under progressive optimizations, sequence length 1000, batch size 16 (Saadat and Fellay 2026 Figure 3) | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TraitGym Complex traits per trait, AUPRC, best of zero-shot and linear probing | 72 evaluations · 72 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TraitGym Complex traits per trait, highest AUPRC among Borzoi tracks from one tissue | 9 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TraitGym Complex traits, AUPRC of a single CADD input feature | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TraitGym Complex traits, global AUPRC of a matching feature | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TraitGym Complex traits, linear-probing, AUPRC by chromosome weighted average | 18 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TraitGym Complex traits, zero-shot, AUPRC by chromosome weighted average | 57 evaluations · 57 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TraitGym fine-mapped GWAS variants, AUPRC after AVI filtering (AlphaGenome Atlas) | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TraitGym Mendelian non-coding variants, AUPRC after AVI filtering (AlphaGenome Atlas) | 2 evaluations · 2 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TraitGym Mendelian traits per trait, AUPRC, best of zero-shot and linear probing | 32 evaluations · 32 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TraitGym Mendelian traits per trait, highest AUPRC among Borzoi tracks from one tissue | 9 evaluations · 9 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TraitGym Mendelian traits, AUPRC of a single CADD input feature | 3 evaluations · 3 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TraitGym Mendelian traits, global AUPRC of a matching feature | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TraitGym Mendelian traits, linear-probing, AUPRC by chromosome weighted average | 18 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TraitGym Mendelian traits, zero-shot, AUPRC by chromosome weighted average | 63 evaluations · 63 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts | 9 evaluations · 15 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| TREC 2020 PM Phase 2: evidence-tier-weighted ranking of retrieved abstracts | 6 evaluations · 10 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| UCSF respiratory RNA mNGS original-testing sensitivity protocol | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| UK Biobank fine-mapped coding variants, AUPRC (GPN-Star Supplementary Table 3) | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| UK Biobank fine-mapped non-coding variants, AUPRC (GPN-Star Supplementary Table 3) | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| UniProtSMB test split (protein-small molecule binding-site prediction) | 4 evaluations · 16 rows | 4 source-scoped figures | Checked result tables available.Scope and remaining work
|
| UNITE cross-validation, cancers with all tumour fractions vs healthy (Wang et al. 2026) | 7 evaluations · 52 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| UNITE cross-validation, cancers with ichorCNA tumour fraction 0 to 0.03 vs healthy (Wang et al. 2026) | 7 evaluations · 46 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| UNITE cross-validation, cancers with ichorCNA tumour fraction above 0.03 to 0.1 vs healthy (Wang et al. 2026) | 7 evaluations · 52 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| UNITE cross-validation, cancers with ichorCNA tumour fraction above 0.1 vs healthy (Wang et al. 2026) | 7 evaluations · 43 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| vcc2026-val-1 · 2026 validation contexts A, B and C | 1,048 evaluations · 1,048 rows | 14 source-scoped figures | Checked result tables available.Scope and remaining work
|
| VHH computational pass rate under TorchScore confidence and ESM2 perplexity | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| VHH expression against ESM2-150M perplexity: Pearson correlation | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| VHH expression against ESM2-150M perplexity: Spearman correlation | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| VHH expression classification by ESM2-150M perplexity: Matthews correlation coefficient | 1 evaluation · 1 row | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ViroBench ALL viruses host classification, G-Split, Macro-F1 | 76 evaluations · 76 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ViroBench ALL viruses host classification, T-Split, Macro-F1 | 76 evaluations · 76 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ViroBench ALL viruses taxonomy classification, G-Split, Macro-F1 | 76 evaluations · 76 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ViroBench ALL viruses taxonomy classification, T-Split, Macro-F1 | 76 evaluations · 76 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ViroBench DNA viruses host classification, G-Split, Macro-F1 | 76 evaluations · 76 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ViroBench DNA viruses host classification, T-Split, Macro-F1 | 76 evaluations · 76 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ViroBench DNA viruses taxonomy classification, G-Split, Macro-F1 | 76 evaluations · 76 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ViroBench DNA viruses taxonomy classification, T-Split, Macro-F1 | 76 evaluations · 76 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ViroBench RNA viruses host classification, G-Split, Macro-F1 | 76 evaluations · 76 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ViroBench RNA viruses host classification, T-Split, Macro-F1 | 76 evaluations · 76 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ViroBench RNA viruses taxonomy classification, G-Split, Macro-F1 | 76 evaluations · 76 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| ViroBench RNA viruses taxonomy classification, T-Split, Macro-F1 | 76 evaluations · 76 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Virtual CRISPR Difficult Benchmark: hit prediction for complex phenotypes | 3 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Virtual CRISPR Simple Benchmark: yes/no prediction of a screen hit | 28 evaluations · 100 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Virus hits against RT-PCR: true and false positives, PPV and hit-level sensitivity (de Vries et al. 2021 Supplementary Table 4) | 13 evaluations · 78 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot family classification, RfamSample (561 Rfam families), CLS embedding, 1 − OR (mean over repeated random samplings of sequence pairs) | 35 evaluations · 35 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot family classification, RfamSample (561 Rfam families), CLS embedding, AUC (mean over repeated random samplings of sequence pairs) | 37 evaluations · 37 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot family classification, RfamSample (561 Rfam families), CLS embedding, F1 (mean over repeated random samplings of sequence pairs) | 37 evaluations · 37 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot family classification, RfamSample (561 Rfam families), CLS embedding, MCC (mean over repeated random samplings of sequence pairs) | 37 evaluations · 37 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot family classification, RfamSample (561 Rfam families), FFT embedding, 1 − OR (mean over repeated random samplings of sequence pairs) | 35 evaluations · 35 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot family classification, RfamSample (561 Rfam families), FFT embedding, AUC (mean over repeated random samplings of sequence pairs) | 37 evaluations · 37 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot family classification, RfamSample (561 Rfam families), FFT embedding, F1 (mean over repeated random samplings of sequence pairs) | 37 evaluations · 37 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot family classification, RfamSample (561 Rfam families), FFT embedding, MCC (mean over repeated random samplings of sequence pairs) | 37 evaluations · 37 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot fitness, RNAGym ncRNA DMS assays (31 assays), PLL-D, AUC (mean over assays) | 35 evaluations · 35 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot fitness, RNAGym ncRNA DMS assays (31 assays), PLL-D, AUC (median over assays) | 35 evaluations · 35 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot fitness, RNAGym ncRNA DMS assays (31 assays), PLL-D, MCC (mean over assays) | 35 evaluations · 35 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot fitness, RNAGym ncRNA DMS assays (31 assays), PLL-D, MCC (median over assays) | 35 evaluations · 35 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot fitness, RNAGym ncRNA DMS assays (31 assays), PLL-D, SR (mean over assays) | 35 evaluations · 35 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot fitness, RNAGym ncRNA DMS assays (31 assays), PLL-D, SR (median over assays) | 35 evaluations · 35 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot fitness, RNAGym ncRNA DMS assays (31 assays), WT-LLR, AUC (mean over assays) | 22 evaluations · 22 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot fitness, RNAGym ncRNA DMS assays (31 assays), WT-LLR, AUC (median over assays) | 22 evaluations · 22 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot fitness, RNAGym ncRNA DMS assays (31 assays), WT-LLR, MCC (mean over assays) | 22 evaluations · 22 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot fitness, RNAGym ncRNA DMS assays (31 assays), WT-LLR, MCC (median over assays) | 22 evaluations · 22 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot fitness, RNAGym ncRNA DMS assays (31 assays), WT-LLR, SR (mean over assays) | 22 evaluations · 22 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot fitness, RNAGym ncRNA DMS assays (31 assays), WT-LLR, SR (median over assays) | 22 evaluations · 22 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot RNA type classification, ArchiveII-Nr (1273 RNAs), CLS embedding, 1 − OR (mean over repeated random samplings of sequence pairs) | 35 evaluations · 35 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot RNA type classification, ArchiveII-Nr (1273 RNAs), CLS embedding, AUC (mean over repeated random samplings of sequence pairs) | 37 evaluations · 37 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot RNA type classification, ArchiveII-Nr (1273 RNAs), CLS embedding, F1 (mean over repeated random samplings of sequence pairs) | 37 evaluations · 37 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot RNA type classification, ArchiveII-Nr (1273 RNAs), CLS embedding, MCC (mean over repeated random samplings of sequence pairs) | 37 evaluations · 37 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot RNA type classification, ArchiveII-Nr (1273 RNAs), FFT embedding, 1 − OR (mean over repeated random samplings of sequence pairs) | 35 evaluations · 35 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot RNA type classification, ArchiveII-Nr (1273 RNAs), FFT embedding, AUC (mean over repeated random samplings of sequence pairs) | 37 evaluations · 37 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot RNA type classification, ArchiveII-Nr (1273 RNAs), FFT embedding, F1 (mean over repeated random samplings of sequence pairs) | 37 evaluations · 37 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot RNA type classification, ArchiveII-Nr (1273 RNAs), FFT embedding, MCC (mean over repeated random samplings of sequence pairs) | 37 evaluations · 37 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot secondary structure, TS test set (70 PDB structures), attention, F1 score (mean over structures) | 32 evaluations · 32 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot secondary structure, TS test set (70 PDB structures), attention, F1 score (median over structures) | 32 evaluations · 32 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot secondary structure, TS test set (70 PDB structures), attention, MCC (mean over structures) | 32 evaluations · 32 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot secondary structure, TS test set (70 PDB structures), attention, MCC (median over structures) | 32 evaluations · 32 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot secondary structure, TS-Hard test set (15 PDB structures), attention, F1 score (mean over structures) | 32 evaluations · 32 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot secondary structure, TS-Hard test set (15 PDB structures), attention, F1 score (median over structures) | 32 evaluations · 32 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot secondary structure, TS-Hard test set (15 PDB structures), attention, MCC (mean over structures) | 32 evaluations · 32 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Wang et al. 2026 zero-shot secondary structure, TS-Hard test set (15 PDB structures), attention, MCC (median over structures) | 32 evaluations · 32 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| WES FASTQ-to-VCF runtime and cost on GCP, Sentieon versus Parabricks (Franzoso et al. 2025 Table S2) | 2 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| WGS FASTQ-to-VCF runtime and cost on GCP, Sentieon versus Parabricks (Franzoso et al. 2025 Table S2) | 2 evaluations · 18 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| WGS germline pipeline wall-clock, DeepVariant calling stage (Samarakoon et al. 2025 Table S3b.2) | 4 evaluations · 40 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| WGS germline pipeline wall-clock, HaplotypeCaller or DRAGEN GSVC calling stage (Samarakoon et al. 2025 Table S3b.1) | 5 evaluations · 50 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| WGS germline pipeline wall-clock, read mapping stage (Samarakoon et al. 2025 Table S3a) | 5 evaluations · 50 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| WGS germline pipeline wall-clock, total of read mapping and HaplotypeCaller or DRAGEN GSVC (Samarakoon et al. 2025 Table S3c) | 5 evaluations · 49 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| WT1 exon 9 saturation MPSA: transcriptome-normalised sensitivity at a 10% background call rate (Smith and Kitzman Table S2) | 8 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Xu and Feng 2026: GI cancer vs non-cancer on GSE149438, three train-validation-test split-runs, DMR-informed CpG features | 5 evaluations · 15 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ye et al. 2026 GRN reconstruction, TFs+1000, cell-type-specific ChIP-seq reference | 147 evaluations · 294 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ye et al. 2026 GRN reconstruction, TFs+1000, non-specific ChIP-seq reference | 147 evaluations · 294 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ye et al. 2026 GRN reconstruction, TFs+1000, OmniPath reference | 147 evaluations · 294 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ye et al. 2026 GRN reconstruction, TFs+1000, STRING reference | 147 evaluations · 294 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ye et al. 2026 GRN reconstruction, TFs+500, cell-type-specific ChIP-seq reference | 147 evaluations · 294 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ye et al. 2026 GRN reconstruction, TFs+500, non-specific ChIP-seq reference | 147 evaluations · 294 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ye et al. 2026 GRN reconstruction, TFs+500, OmniPath reference | 147 evaluations · 294 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Ye et al. 2026 GRN reconstruction, TFs+500, STRING reference | 147 evaluations · 294 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Yoruba LCL dsQTL classification (AlphaGenome paper) | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Yoruba LCL dsQTL effect-size prediction (AlphaGenome paper) | 3 evaluations · 3 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Zeng et al. 2026 independent PE validation dataset: cancer vs healthy | 10 evaluations · 19 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation | 10 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zeng et al. 2026 primary SE dataset: cancer vs healthy, nested cross-validation | 3 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zeng et al. 2026 SE 10% hold-out set: cancer vs healthy | 3 evaluations · 6 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot BRCA1 'Both' (coding and noncoding) SNVs classification (Evo 2 paper, Supplementary Data 1) | 15 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot BRCA1 coding SNVs classification (Evo 2 paper, Supplementary Data 1) | 16 evaluations · 32 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot BRCA1 intronic SNVs classification (Evo 2 paper, Supplementary Data 1) | 15 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot BRCA1 loss-of-function classification, all SNVs (evo2-cloud-operations W1) | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot BRCA1 loss-of-function classification, coding SNVs (missense, nonsense, synonymous) (evo2-cloud-operations W1) | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot BRCA1 loss-of-function classification, missense SNVs (evo2-cloud-operations W1) | 4 evaluations · 4 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot BRCA1 loss-of-function classification, noncoding SNVs (all other consequences) (evo2-cloud-operations W1) | 8 evaluations · 8 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot BRCA1 noncoding SNVs classification (Evo 2 paper, Supplementary Data 1) | 15 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot BRCA1 splice region SNVs classification (Evo 2 paper, Supplementary Data 1) | 15 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot BRCA2 'Both' (coding and noncoding) SNVs classification (Evo 2 paper, Supplementary Data 1) | 14 evaluations · 28 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot BRCA2 coding SNVs classification (Evo 2 paper, Supplementary Data 1) | 15 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot BRCA2 noncoding SNVs classification (Evo 2 paper, Supplementary Data 1) | 15 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot CAGI5 MPRA activity-effect prediction (borzoi-ensemble-matched comparison) (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Zero-shot CAGI5 MPRA activity-effect prediction (chrombpnet-matched comparison) (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Zero-shot ClinVar 'Both' (coding and noncoding) indels classification (Evo 2 paper, Supplementary Data 1) | 10 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar 'Both' (coding and noncoding) microsatellite variants classification (Evo 2 paper, Supplementary Data 1) | 10 evaluations · 20 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar 'Both' (coding and noncoding) SNVs classification (Evo 2 paper, Supplementary Data 1) | 12 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar coding indels classification (Evo 2 paper, Supplementary Data 1) | 15 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar coding microsatellite variants classification (Evo 2 paper, Supplementary Data 1) | 15 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar coding non-SNVs classification (Evo 2 paper, Supplementary Data 1) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Zero-shot ClinVar coding non-SNVs, far from splice site classification (Evo 2 paper, Supplementary Data 1) | 15 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar coding non-SNVs, highly conserved classification (Evo 2 paper, Supplementary Data 1) | 15 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar coding non-SNVs, moderately conserved classification (Evo 2 paper, Supplementary Data 1) | 15 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar coding non-SNVs, not conserved classification (Evo 2 paper, Supplementary Data 1) | 15 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar coding non-SNVs, poorly conserved classification (Evo 2 paper, Supplementary Data 1) | 15 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar coding SNVs classification (Evo 2 paper, Supplementary Data 1) | 18 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar coding SNVs, far from splice site classification (Evo 2 paper, Supplementary Data 1) | 18 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar coding SNVs, highly conserved classification (Evo 2 paper, Supplementary Data 1) | 18 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar coding SNVs, moderately conserved classification (Evo 2 paper, Supplementary Data 1) | 18 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar coding SNVs, near splice site classification (Evo 2 paper, Supplementary Data 1) | 18 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar coding SNVs, not conserved classification (Evo 2 paper, Supplementary Data 1) | 18 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar coding SNVs, poorly conserved classification (Evo 2 paper, Supplementary Data 1) | 18 evaluations · 36 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar low SpliceAI and Pangolin scores (both below 0.1) non-SNVs classification (Evo 2 paper, Supplementary Data 1) | 11 evaluations · 22 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar low SpliceAI and Pangolin scores (both below 0.1) SNVs classification (Evo 2 paper, Supplementary Data 1) | 13 evaluations · 26 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar noncoding indels classification (Evo 2 paper, Supplementary Data 1) | 12 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar noncoding microsatellite variants classification (Evo 2 paper, Supplementary Data 1) | 12 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar noncoding non-SNVs classification (Evo 2 paper, Supplementary Data 1) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Zero-shot ClinVar noncoding non-SNVs, far from splice site classification (Evo 2 paper, Supplementary Data 1) | 12 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar noncoding non-SNVs, highly conserved classification (Evo 2 paper, Supplementary Data 1) | 12 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar noncoding non-SNVs, intergenic classification (Evo 2 paper, Supplementary Data 1) | 12 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar noncoding non-SNVs, moderately conserved classification (Evo 2 paper, Supplementary Data 1) | 12 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar noncoding non-SNVs, near splice site classification (Evo 2 paper, Supplementary Data 1) | 12 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar noncoding non-SNVs, not conserved classification (Evo 2 paper, Supplementary Data 1) | 12 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar noncoding non-SNVs, poorly conserved classification (Evo 2 paper, Supplementary Data 1) | 12 evaluations · 24 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar noncoding SNVs classification (Evo 2 paper, Supplementary Data 1) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| Zero-shot ClinVar noncoding SNVs, far from splice site classification (Evo 2 paper, Supplementary Data 1) | 14 evaluations · 28 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar noncoding SNVs, highly conserved classification (Evo 2 paper, Supplementary Data 1) | 15 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar noncoding SNVs, intergenic classification (Evo 2 paper, Supplementary Data 1) | 14 evaluations · 28 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar noncoding SNVs, moderately conserved classification (Evo 2 paper, Supplementary Data 1) | 15 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar noncoding SNVs, near splice site classification (Evo 2 paper, Supplementary Data 1) | 14 evaluations · 28 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar noncoding SNVs, not conserved classification (Evo 2 paper, Supplementary Data 1) | 15 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot ClinVar noncoding SNVs, poorly conserved classification (Evo 2 paper, Supplementary Data 1) | 15 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot distance-balanced eQTL causality (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Zero-shot enhancer–gene linking (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Zero-shot GTEx splicing-outlier prediction (AlphaGenome paper) | 2 evaluations · 2 rows | 1 source-scoped figures | Checked result tables available.Scope and remaining work
|
| Zero-shot SpliceVarDB 'Both' (coding and noncoding) SNVs classification (Evo 2 paper, Supplementary Data 1) | 15 evaluations · 30 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot SpliceVarDB exonic SNVs classification (Evo 2 paper, Supplementary Data 1) | 16 evaluations · 32 rows | Not yet available | Results available; comparison group not yet validated.Scope and remaining work
|
| Zero-shot SpliceVarDB intronic SNVs classification (Evo 2 paper, Supplementary Data 1) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
Evaluators
9 pages · 0 with results · 0 with charts.
| Page | Evaluations and metric rows | Charts | Collection status |
|---|---|---|---|
| AMBER | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BenchBench-Cloning agreement judge (Claude Mythos 5.1) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BenchBench-Cloning cloning simulator | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BenchBench-Cloning construct-design deterministic graders | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| BenchBench-Cloning rubric judge (GPT-6 Astra) | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| OPAL | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| PoseBusters | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| scPertEval | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|
| TorchScore | 0 evaluations · 0 rows | Not yet available | Published results still to collect.Scope and remaining work
|